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Abstract
Quantitative imaging with

18

F-FDG PET/CT has the potential to provide

an in vivo assessment of response to radiotherapy (RT). However, comparing
tissue tracer uptake in longitudinal studies is often confounded by variations in
patient setup and potential treatment induced gross anatomic changes. These
variations make true response monitoring for the same anatomic volume a
challenge, not only for tumors, but also for normal organs-at-risk (OAR). The
central hypothesis of this study is that more accurate image registration will lead
to improved quantitation of tissue response to RT with 18F-FDG PET/CT.
Employing an in-house developed “demons” based deformable image
registration algorithm, pre-RT tumor and parotid gland volumes can be more
accurately mapped to serial functional images. To test the hypothesis, specific
aim 1 was designed to analyze whether deformably mapping tumor volumes
rather than aligning to bony structures leads to superior tumor response
assessment. We found that deformable mapping of the most metabolically avid
regions improved response prediction (P<0.05). The positive predictive power
for residual disease was 63% compared to 50% for contrast enhanced post-RT
CT. Specific aim 2 was designed to use parotid gland standardized uptake
value (SUV) as an objective imaging biomarker for salivary toxicity. We found
that relative change in parotid gland SUV correlated strongly with salivary
toxicity as defined by the RTOG/EORTC late effects analytic scale (Spearman’s
ρ = -0.96, P<0.01).

Finally, the goal of specific aim 3 was to create a

phenomenological dose-SUV response model for the human parotid glands.

v

Utilizing only baseline metabolic function and the planned dose distribution,
predicting parotid SUV change or salivary toxicity, based upon specific aim 2,
became possible.

We found that the predicted and observed parotid SUV

relative changes were significantly correlated (Spearman’s ρ = 0.94, P<0.01).
The application of deformable image registration to quantitative treatment
response monitoring with 18F-FDG PET/CT could have a profound impact on
patient management. Accurate and early identification of residual disease may
allow for more timely intervention, while the ability to quantify and predict toxicity
of normal OAR might permit individualized refinement of radiation treatment plan
designs.
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“It was an act of desperation. For six years I had struggled with the blackbody
theory. I knew the problem was fundamental and I knew the answer. I had to
find a theoretical explanation at any cost…”
-Max Planck

Chapter 1

Introduction

Implementation

of

anatomic

imaging

modalities,

like

computed

tomography (CT), has found extensive use in the oncologic setting. From initial
staging, to treatment planning, to assessing treatment response, CT is
ubiquitous [1-4].

In 2000, Therase et al. presented the results of a multi-

institutional collaborative effort to evaluate the existing criteria for treatment
response in solid tumors set forth by the World Health Organization (WHO) in
the 1970s [5].

The new guidelines specified the preferred use of imaging

techniques over clinical evaluation to establish response in solid tumors based
upon visible reduction in the size of the tumor. The criteria established that for
measurable tumors,≥ 10 mm in at least one dimension, the complete
disappearance of all target lesions is a complete response, a 30% reduction in
the longest diameter of target lesions is a partial response, and a 20% increase
in the longest diameter of the target lesion is deemed progressive disease.
Stable disease is defined as having insufficient shrinkage or enlargement to
classify as partial response or progressive disease, respectively.

However, lesion measurement with anatomic imaging modalities has
been shown to be a poor prognostic tool for response to therapy [6-11]. In one
study by Jones et al., 56% of patients had incorrect CT-based T-staging when
1

compared to surgically resected specimens [3].

For regional metastases,

decreases in the largest axial dimensions of lymph nodes calculated from CT
images were not found to be a significant predictor of positive surgical
specimens [7]. These difficulties are not limited to CT imaging. While magnetic
resonance imaging (MRI) may have superior soft tissue contrast, previous
studies have demonstrated similarly poor results in predicting tumor response
[6].

One of the major obstacles in predicting response to treatment with

anatomic modalities is differentiating residual disease from necrosis or
surrounding normal tissue.

However, it is expected that imaging functional

change in target tissues, which often precedes visible anatomic change, may
improve outcome prediction [12, 13].

Functional Response Monitoring

In recent years, positron emission tomography (PET) using the
radiolabeled glucose analog, Fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG),
has gained favor in the oncology setting [14-18].

Exploiting an increased

reliance on glycolysis for energy production, the preferential uptake of

18

F-FDG

by malignant tissue provides excellent tumor to background contrast. Multiple
studies have demonstrated the superiority of PET in the staging of cancers over
anatomic based modalities [19].

Sensitivities and specificities found in the

literature range from 84% to 86% and 88% to 93%, respectively.

With the

development of integrated PET/CT systems, inherently co-registered functional
and anatomic images have further improved the usefulness of this modality [9].

2

Veit-Haibach et al. assessed the accuracy of PET, CT, and PET/CT in staging
head and neck cancers and found integrated PET/CT to be significantly more
accurate in overall TNM staging [20].

The concentration of radiolabeled tracers can be assessed in two general
ways: qualitative and quantitative. In qualitative assessment the experienced
nuclear medicine physician compares the intensity and distribution of FDG to
normal surrounding tissues, like the liver, in order to classify patients as being
PET positive or negative. However, this method can be limited by equivocal
FDG-uptake[21].

The second method of assessment is quantitative. Uptake of FDG into
cancer cells is directly related to the number of viable cells [22]. Therefore,
calculation of uptake reduction should be a surrogate of tumor cell killing. The
net rate of

18

F-FDG trapped within the cell can be calculated through graphical

analysis using the Patlak-Gjedde plot. Utilizing the following equation,

T

c(t ) = λ * c p (t ) + K i ∫ c p (t )dt
0

where, c(t) is the activity concentration measured by the imaging system at time
t, cp(t) is the activity concentration in the plasma, Ki is the rate of activity transfer
into tissue, and λ*cp(t) is non-trapped FDG in tissue a plot of the area under the
time activity curve versus the activity concentration in the tissue with a slope
equal to Ki can be found with simple linear regression analysis [23].

This

3

analysis is often simplified and activity concentration can be quantified with the
standardized uptake value (SUV) [20]. The SUV is a simplified version of the
equation used in the Patlak-Gjedde analysis. The basic assumption is that if the
imaging time point is sufficiently far from the injection time point the activity
concentration will be linearly correlated with FDG trapped in the tissue. The time
activity curve is assumed to be proportional to the injected dose normalized by
some factor describing the distribution of activity in the patient. One common
normalization factor is patient mass [24].

The concentration of FDG in the

plasma at this late time point is expected to be very low, i.e., λ*cp(t) is assumed
to be zero. The SUV can then be computed using the following relation,

K iα

Qi [ MBq / mL]
= SUVBW
Qinjected [ MBq]
W [ Kg ]

where Qi represents the concentration of radiotracer in the tumor or tissue of
interest, Qinjected is the injected activity, and W is the patient weight in kilograms
[24]. The SUV has been shown to correlate well with more intensive methods of
calculating tissue activity concentration [25].

Effects of Anatomic Deformation and Patient Set-up Variation

Comparing the same anatomic volume on serial imaging studies is
challenging due to two main factors: treatment induced anatomic changes and

4

patient setup variation.

Considering the former, multiple studies have

demonstrated the potential anatomic variation in head and neck cancer patients
resulting from treatment induced tumor and nodal contraction and weight loss.
Barker et al. utilized daily CT imaging of head and neck cancer patients with an
integrated CT-linear accelerator system and found the gross tumor volume
(GTV) decreases at a median rate of 1.8% per treatment day culminating in a
total loss of 70% of the initial volume. The center of mass had shifted position
asymmetrically by a median of 3.3 mm. For the parotid glands, the median
volume was found to decrease 0.19 cm3 per day with a median medial shift of
3.1 mm that correlated with weight loss. In figure 1.1, an extreme example of
treatment induced anatomic change and patient setup variation is illustrated.
Previous response monitoring studies have largely ignored the effects of
anatomic and patient setup variation. By utilizing SUVMAX, the maximum pixel
value in an FDG-avid region, to sample tumor burden, the vast majority of
investigators were able to avoid the need to accurately map baseline volumes to
post-RT imaging studies. However, SUVMAX is not an optimal metric because of
its strong dependence on noise. In studies where region based analysis was
employed, the solution to anatomic and setup variation is usually rigid
registration. However, as depicted in figure 1.1 d), rigid alignment of the GTV
and parotid contours on post-RT studies appears to be entirely inadequate. The
rigidly aligned contours extend beyond the patient’s anatomy and contain
undesired tissue types, as can be seen for the right parotid contour in figure 1 d).
The main goal of this project is to improve quantitation in treatment response

5

monitoring with

18

F-FDG PET/CT.

To achieve this goal we will combine

advanced image registration techniques with RT treatment designs and serial
functional images.

Tumor Response

The potential of PET/CT to improve treatment response monitoring in cancer
patients has been noted for some time. In one early study from 1994, Greven et
al. found that 6 of 7 head and neck cancer patients with increasing FDG
accumulation following RT were positive for persistent disease, while all
responding patients were found to have decreases in tracer uptake [26]. Since
this initial study multiple reports have investigated 18F-FDG PET/CT to determine
its effectiveness in response monitoring [19]. Studies by Allal et al., Kitagawa et
al., and Kao et al. found that SUVMean performed well as a predictor for local
control in head and neck cancers [27-29].

One recent study by Yao et al.

demonstrated the high negative predictive value of SUV in response monitoring
studies (roughly 99%) [30]. In contrast, studies by Arslan et al., Yen et al., and a
follow-up by Greven et al. found quantitative measurement of FDG-uptake not to
be useful in response monitoring [31-33].

6

a)

c)

b)

d)

Figure 1.1 Extreme anatomic and setup variation

An extreme example of setup and anatomic variation possible in response
monitoring studies between pre-RT CT (a and c) and the post-RT CT (b and d)
imaging studies. Axial views are presented with parotid (orange) and gross
tumor volume contours (maroon) as originally contoured on the planning CT
images and rigidly aligned to the C2 vertebra.

7

A recent study by Moeller et al. found that while SUV was significantly different
between responding and non-responding patients, it offered no improvement
over conventional CT in positive (58% vs. 50%) and negative predictive values
(96% vs. 97%) and little improvement in positive predictive value (57% vs. 50%)
[34]. These examples illustrate that quantitative treatment response monitoring
with PET/CT has yet to live up to its initial promise.

While many studies have supported the overall philosophy behind PET
imaging of tumor response, namely that reduced uptake of

18

F-FDG generally

corresponds to better prognosis for patients, questions still remain. Consider the
issue of sampling FDG-uptake on PET images. By far the most popular metric
to assess tumors has been SUVMax. The justification frequently cited for its use
is that the term represents the maximum tumor burden. However, SUVMax is
known to be strongly affected by image noise. In studies by Boellard et al. and
Falen et al., SUVMax variations in excess of 50% were observed [35, 36].
Alternatively, region-of-interest (ROI) based analysis may be used to determine
an average tissue uptake. With volume based techniques, the question then
arises of whether automated or manually defined regions should be utilized.
More recently, SUVPeak has been suggested as metric to assess tumor viability.
SUVPeak is defined as an approximately 1 cm3 volume centered on the maximum
pixel value [37]. In light of expected anatomic changes discussed earlier,
recommendations to compare the same volume on serial imaging studies
present profound challenges [38].

8

Normal Tissue Response

Treatment of head and neck cancer often results in the salivary glands
receiving high mean doses of radiation (28 to 45 Gy) [39]. Irradiation of the
parotids can lead to reduced salivary flow and the subjective assessment of dry
mouth, called xerostomia [40, 41].

Xerostomia is the primary morbidity

associated with RT for head and neck cancers with 65% of patients reporting
severe to moderate xerostomia after one year [40]. Saliva produced by the
major and minor salivary glands plays a vital role in mastication, speaking, and
the mucosal immune system with the parotid glands producing the majority of
the salivary volume (approximately 60%). Salivary flow reduction can affect not
only quality of life (QOL), but lead to oral fissures, infection, and potential
malnutrition [40].

Salivary function is typically evaluated with patient self-

reported QOL questionnaires to gauge the severity of xerostomia, or
measurement of saliva volume [42]. However, these techniques often perform
poorly and have large variations.

Imaging salivary gland function offers a non-invasive method to assess
radiation induced damage. Salivary gland scintigraphy (SGS) is one method
that has been utilized to image salivary function by measuring the concentration
of

99m

Tc-pertechnetate remaining in the glands following the administration of a

salivation inducing agent [43].

Previous reports assessing function after RT

have found good correlations between activity concentrations measured with
scintigraphy and saliva volume [44]. Recently, SGS has been used to perform

9

dose-response analysis in the parotid glands [45, 46].

However, these

techniques were limited to 2D planar images of the salivary glands without any
inherently aligned anatomic images.

Given the parotid gland shrinkage and

medial shifting discussed above, automatic alignment of pre-RT volumes is
desirable. With the increasing use of

18

F-FDG PET/CT in initial staging and

follow-up for head and neck cancers, incidental collection of parotid uptake may
prove to be a readily accessible alternative to additional nuclear medicine
studies or salivary flow measurements.

10

Central Hypothesis

We hypothesize that more accurate image registration will lead to
improved quantitation of tissue response to radiotherapy with

18

F-FDG PET/CT

imaging.

Specific aim 1

To apply deformable image registration techniques to images acquired during a
prospective clinical trial designed to assess and predict RT outcomes with

18

F-

FDG PET/CT.

Working Hypothesis:

Voxel-by-voxel mapping of primary tumor volumes to

serial 18F-FDG PET/CT scans will significantly improve region based quantitative
tumor response analysis.

Specific aim 2.a

Evaluate the potential to determine normal organ-at-risk (OAR) toxicity in
patients treated with intensity modulated radiotherapy (IMRT) for head and neck
cancers with 18F-FDG PET/CT.

Working Hypothesis: Relative change in parotid gland uptake of

18

F-FDG will

function as an objective imaging biomarker of oral complication following RT.

11

Specific aim 2.b

To quantify and model the planned-dose-functional-response relationship of the
parotid glands in head and neck cancer patients treated with IMRT.

Working Hypothesis:

A predicted imaging biomarker for oral complication

following RT will correlate closely with whole mouth stimulated salivary flow.

12

Chapter 2

Radiotherapy and the Head and Neck

Cancers of the Head and Neck

Head and neck cancers make up roughly 6% of all cancers diagnosed in
the United States. This corresponds to 46,000 patients suffering from a cancer
originating in the head and neck region each year.
individuals will die from this disease in the US.

An estimated 11,000

Worldwide, over 600,000

patients will be diagnosed with 350,000 deaths. The majority of these cancers
arise in the epithelial cells that form the protective linings of cavities and are
known as squamous cell carcinomas [47]. This makes alcohol and tobacco
consumption significant risk factors for this histology [48]. Additional risk factors
include human papilloma virus (HPV) infection, poor oral hygiene, wood dust
inhalation, and asbestos to name a few. The primary disease sites of the head
and neck regions are the nasopharynx, oropharynx, hypopharynx, and larynx.
Among males, cancers of the pyriform sinus, in the hypopharynx, contribute the
most patients per 100,000 (2.33) in the US. In females, cancers at this site also
supply the most patients (1.67).

Treatment of Head & Neck Cancers

The majority of patients with head and neck cancers present with
advanced disease (Stage III and IV), with only about 1/3 presenting with early

13

stage disease [48]. Although staging varies between sites, primary advancedstage tumors in the head and neck are typically approximately 4 cm in size as
defined by the American Joint Commission on Cancer (AJCC).

Typical

treatment strategies for late stage disease are surgery, radiation, and
chemotherapy. Progression free survival rates seen for all cancers of the oral
cavity, oropharynx, hypopharynx, and larynx are 36% at five years with overall
survival rates of approximately 40% [49-51]. The concurrent delivery of
chemotherapeutic agents like cisplatin can improve 5-year disease free survival
to 47% with overall survival rates of 53% [50]. Intensity modulated radiation
therapy (IMRT) has shown promising results in terms of locoregional control
94%, but acute toxicity results have not been favorable [52, 53].

Typical

treatments for head and neck cancers consist of cumulative doses of 63 – 70 Gy
given in 30 – 35 fractions of 1.8 – 2.2 Gy 5 days/week. Alternative fractionations
schedules have also led to improvements in 5-year disease free survival.
Hyperfractionation regimens have been shown to offer 8% absolute benefit.
Phase III clinical trials have led to recurrence rates within the first two years of at
least 50% [54, 55].

Treatment following failure is often salvage surgery or

systematic therapy with methotrexate [56].

Another option that has led to

improvement in progression free survival is re-irradiation. With the recurrence
rates seen in this patient population early identification of residual disease is
critical for patient management and the use of additional therapies.

Because of the complex anatomy in the head and neck region normal
tissue complications are common. Loss of taste, dysphagia, dental carries, and

14

hearing loss are common symptoms [57]. One of the more frequent morbidities
is radiation-induced xerostomia. Up to 65% of patients will report oral dryness
one year after treatment [40]. Prevention strategies do exist, but the high doses
delivered make damage to the salivary glands a significant issue.

The Human Salivary System

Saliva is a vital body fluid.

It performs crucial roles in mastication,

digestion, swallowing, oral fauna regulation, and speech. Saliva is composed of
approximately 99% water. Other constituents include, but are not limited to,
lipids, amino acids, and proteins. The protein components consist primarily of αamylase (30%) which begins the digestion of polysaccharides.

Additionally,

saliva provides an excretory route for metabolic waste products like urea. The
secretory function of the salivary glands is controlled by the autonomic nervous
system. Saliva production can be stimulated through taste, smell, chewing, or
exogenous stimulants [41].

Saliva is produced primarily in three paired organs in the upper
aerodigestive tract.

However, there are multiple minor salivary glands

distributed throughout the buccal cavity. The number and arrangement will vary
among patients. The three major paired glands are: the parotid, submandibular,
and sublingual glands. The major salivary glands produce over a liter of saliva
per day [58]. The parotid glands can produce anywhere from roughly half of the
salivary volume up to 70% of the total volume. However, saliva produced in the
parotid glands is primarily created during stimulation.

In unstimulated

15

conditions, the contribution is much smaller with the submandibular glands
taking the dominant role, producing as much as 80% of the saliva volume. The
sublingual glands are typically responsible for 2 -5% of the saliva produced [5961].

The major salivary glands have a well defined structure. The organs
consist of ducts, myoepithelial cells, connective tissue, and the saliva producing
unit, the acini. The acinar cells may be either mucous or serous exocrine cells.
The acinar cells are contained in many spherical clusters throughout the glands.
Radiating across the acinar cell, the processes of myoepithelial cells embrace
the acinar cell and contract to force saliva into the collecting ducts.

The

myoepithelial cells comprise about 1.6% of the volume of the parotid glands [60].
Saliva moves through the secondary ductile system and into the intraglandular
main duct.

In the case of the parotid glands, the saliva then traverses the

extraglandular segment of Stensen’s duct which is superficial to the masseter
muscle before entering the buccal cavity through the orifice of Stensen’s duct.
The parotid glands contain serous acinar cells, while the submandibular and
sublingual glands contain both serous and mucous acinar cells. Qualitatively,
the saliva produced in the submandibular and sublingual glands is thick and
sticky, with the parotids producing a watery product.

Salivary function can be diminished by many factors e.g., pathologic
sources like Sjogren’s syndrome or through damage induced by ionizing
radiation. Patients receiving radiation therapy for head and neck cancers will
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routinely experience high doses to the salivary glands. However, decreases in
salivary flow are detectable in as little as 24 hours after doses as small as 2 Gy
[62]. Within the first week of treatment salivary flow rates can drop by 50% or
more [63-65].

Salivary flow rates will continue to decline throughout the

treatment course. In one study of IMRT designed to spare the salivary glands,
the contralateral and ipsilateral parotid glands received mean doses of 22 Gy
and 55 Gy, respectively, whereas mean doses to the ipsilateral submandibular
gland were on the order of 67 Gy. Contralateral submandibular glands receive
mean doses of 58 Gy [42]. No appreciable salivary output was measured for the
ipsilateral glands. On the other hand, measured salivary flow for contralateral
parotid glands decreased initially, but approached pre-RT levels at one year
post-RT [42].

Parotid Radiosensitivity

The response of salivary gland constituent tissue to ionizing radiation is
complex and not well understood. The saliva producing units of the salivary
glands, acinar cells, are the assumed targets in radiation damage leading to
reduced salivary flow. The acinar cells are reverting postmitotic cells. Cells of
this type will exhibit little regular division and variable differentiation.
Consequently, these targets are expected to be relatively less radiosensitive
than lymphocytes, for instance, and exhibit mostly late effects.

However, as discussed above reduced salivary flow can be detected in as
little as 24 hours. One classic explanation is that radiation induced apoptosis is
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responsible for the high acute radiosensitivity of the acinar cells, yet studies in
rhesus monkeys failed to identify appreciable levels of apoptosis [66, 67].
Additionally, similarly low levels of apoptosis, less than 2%, have been observed
in rat acinar cells [68]. Further complicating the picture, Roesink et al., using
salivary gland scintigraphy, observed that while uptake of radiotracer was not
diminished in the salivary glands, salivary flow was reduced.

To account for the complicated radiation response observed in the
salivary glands, hybrid models of radiosensitivity have been proposed. In one
model proposed by Konings et al., the acute radiosensitivity was proposed to
result from radiation damage to the plasma membrane of the secretory cells
[69]. The proposed model is similar to the indirect action of radiation model that
results in damage to nuclear DNA. Briefly, after interaction with a photon, a
water molecule becomes ionized. The chemical reaction is,

H 2O → H 2O + + e −
where, H2O+ is the ion radical. The ion radical has a short lifetime and decays to
form a free radical, which has an unpaired electron. The chemical reaction to
form the hydroxyl radical, OH is,

H 2O + + H 2O → H 3O + OH
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The highly reactive hydroxyl radical is responsible for much of the damage to
nuclear DNA. Damage to the cellular membrane is initiated by a process known
as lipid peroxidation.

In this reaction, the oxygen radical targets the

phospholipids that make up the cell membrane. After removing hydrogen from
the fatty acid chain, a lipid alkyl radical will be formed. The lipid alkyl radical
then reacts with oxygen to form a peroxyl radical. The peroxyl radical then
removes a hydroxyl radical from the neighboring fatty acid chain, producing new
alkyl radicals and inducing a chain reaction.

One of the many effects of

peroxidation of cellular membrane lipids is the disruption of membrane
receptors. The disruption of the cell signaling pathway for saliva secretion is
hypothesized to be the source of the acute response of the parotid glands to
ionizing radiation [70].

The mechanism for late damage is the lack of cell replacement due to the
loss of progenitor cells.

The progenitor cells in the parotid acini are located at

the distal segments of the ductile system. This classic model of late response is
supported by studies in the rat parotid [71]. Following irradiation with 30 Gy, the
parotid glandular connective tissue increased from 10% to 60% of the volume.
The relative number of acinar cells decreased from 80% to 20% of the volume.
Following these histopathological findings, the salivary flow was reduced by
90%.

Extensive studies have been carried out to assess the functional outcome
the parotid glands after RT. In one study from Eisbruch et al., salivary flow
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measurements were collected from 88 patients at multiple times points up to 1
year post-RT [42].

Parotid gland response was best described by dose

thresholds. Significantly higher unstimulated salivary flow was seen for glands
receiving a mean whole organ dose less than 24 Gy.

For stimulated flow,

parotid glands receiving a mean dose less than 26 Gy had significantly better
function.

Chao et al. observed that the parotid glands lose function

exponentially with dose. Specifically, the parotid glands were found to lose 5.4%
of the stimulated salivary flow at 6 months for every Gy delivered [39].

In

contrast, Roesink et al. observed parotid gland functional response to be best
described as linear with no threshold dose [45]. While the exact functional form
of dose response for parotid gland functional response remains unknown,
keeping the mean dose to the parotid glands less than or equal to 26 Gy has
been shown to be a significant predictor of salivary toxicity. The TD50/5 for the
parotid glands is 46 Gy [72].

Assessing Salivary Toxicity

Assessing salivary toxicity is accomplished primarily through two
methods: objective and subjective. Objective evaluation may take the form of
physician assessment based upon the Radiation Therapy and Oncology Group
(RTOG) and European Organization for Research and Treatment of Cancer
(EORTC) SOMA scale [73, 74]. Graded 1 – 4, representing increasing severity
of toxicity, the scale is meant to capture the response of individual organs.
Another method of objective assessment is measurement of the saliva produced
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by each of the major glands or from the whole mouth with saliva mixed. Based
upon relative changes in the quantity of salvia produced, the EORTC/RTOG
scale can be utilized to also assign a grade, 1 – 4, to the salivary toxicity.
Subjective evaluation is primarily carried out through patient self-reported quality
of life questionnaires [75]. The patient answers a series of questions relating his
or her difficulty at performing common tasks like speaking or eating as a result of
dryness.

Each question is ranked on a 1 – 10 Likehart scale and a final

summary xerostomia qualify of life (XQL) score can be calculated for the
questionnaire.

Each metric has limitations. Because xerostomia is the perception of dry
mouth, patient self-reported scores may best reflect the symptoms experienced
by the patient, but these are fundamentally limited by their subjective nature. On
the other hand, XQL scores have been shown to correlate significantly with
measured salivary flow rates [76]. In the case of physician assessed toxicity,
salivary flow rates were not found to correlate with xerostomia grade [76].
Interestingly, physician assessment was found to underestimate the severity of
toxicity when compared to patient self-reported scores.

Finally, for

measurements of salivary flow, large normal ranges are often found. In one
study by Ship et al., untreated individuals with the lowest and highest 10th
percentiles of produced saliva mass had similar oral health [77].

Further

complicating the use of salivary flow are large intra-patient variations that have
been observed on the order of 50%.

The poor performance of these
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cumbersome additional procedures coupled with ambiguous endpoints presents
an opportunity for novel methods to assess salivary toxicity.
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Chapter 3

Specific Aim 1

To apply deformable image registration techniques to images acquired during a
clinical trial designed to assess and predict RT outcomes with 18F-FDG PET/CT.

Working Hypothesis: Voxel-by-voxel mapping of primary tumor volumes
to serial

18

F-FDG PET/CT images will improve quantitative tumor

response analysis.

Purpose:

Assessing and predicting the response of tumors to RT has long been the
goal of PET imaging.

The ability to differentiate responding from non-

responding tumors before response is detectable through measurement of gross
disease holds great promise. A question of fundamental importance is whether
response should be assessed using the total tumor volume or the most
aggressive regions of the initial tumor. Once a decision has been made as to
the appropriate volume to assess response to RT, the question of how to align
this volume on the subsequent imaging studies must be answered. To address
this question, four arms were tested in specific aim 1.

The first two arms this specific aim attempted illuminate which volume
delineation method should be preferred for predicting and assessing response to
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RT with

18

F-FDG PET/CT.

Total tumor volumes as well as the most

metabolically active volumes defined on both PET and CT images were utilized
to answer this question. Second, each arm was split into two arms to test the
preferred alignment technique. A deformable image registration algorithm and a
bony alignment method were utilized to align the pre-RT volumes across the
serial imaging studies.

Early identification of patients not responding to

treatment may allow for more timely alteration in patient management.

Methods and Materials:

Patient Cohort

Patients were enrolled into an IRB approved protocol (LAB07-0043) at
The University of Texas MD Anderson Cancer Center (MDACC) designed to
assess and predict, prospectively, radiotherapy (RT) outcomes using serial
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F-

FDG PET/CT. Eligible adults had biopsy-proven stage III-IVb (American Joint
Committee on Cancer) squamous cell carcinoma of the oropharynx,
hypopharynx, or larynx with scheduled intensity modulated RT (IMRT) or
chemoradiotherapy. Between 2005 and 2007, 107 patients were screened for
enrollment.

All patients were scheduled for one pre-RT

18

F-FDG PET/CT study

collected within four weeks prior to the beginning of treatment.

Follow-up

PET/CT studies were performed approximately 8 – 9 weeks after the completion
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of treatment.

All functional imaging studies were performed with integrated

PET/CT systems.

Initial follow-up was performed eight to nine weeks after the completion of
treatment. Follow-up radiographic, clinical, and pathologic evidence served as
the gold standard for assessing patient outcome. Patients with no evidence of
disease clinically or radiographically were continually monitored and considered
as RT responders. Patients with residual or recurrent disease at the time of
follow-up were considered RT non-responders.

RT and Systemic Treatment

Patients screened for inclusion followed two general therapeutic
pathways. In one arm, patients received only IMRT; in the second arm, patients
received concurrent systemic therapy with IMRT. Treatment plans were created
with the Pinnacle3 treatment planning system (Philips Medical Systems,
Andover, MA). The typical prescription dose was 70 Gy given 5 days a week in
2.12 Gy fractions. Other dose prescriptions used for this cohort were 1.8 Gy/fx,
2.0 Gy/fx, and 2.2 Gy/fx. Patients were not stratified based upon varying doses
per fraction.

Functional Imaging

PET imaging studies were performed with the integrated GE Discovery
(GE Medical Systems, Milwaukee, Wisconsin) PET/CT systems.

Following

collection all images were transferred to the institutional digital archival system.
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Patient preparation for F-FDG PET/CT imaging was crucial to establish uniform
collection conditions of all functional studies. Patients were instructed to fast for
at least four hours prior to injection of F-FDG radiotracer. It is important for
patients to maintain a high protein-low carbohydrate diet, abstaining from sugary
drinks, but still maintaining hydration. Reducing the blood glucose concentration
will reduce uptake competition between injected FDG and consumed
carbohydrates.

Prior to imaging, serum glucose levels were measured and

patients found to have levels greater than 200 mg/dL were not imaged. Patient
height (m) and weight (kg) were also recorded. Imaging subjects were then
instructed to lie supine and minimize movement to reduce the accumulation of
FDG in muscle.

Tracer was injected intravenously with a 20 – 23 gauge intracatheter.
Institutional guidelines specify the injection of 5 – 20 mCi of 18F-FDG followed by
a saline flush of 10 – 20 cm3. Following injection, procedural recommendations
specify a 30 – 45 minute waiting period to allow the tracer to be absorbed
throughout the patient’s tissues.

American College of Radiology Imaging

Network (ACRIN) guidelines stipulate that imaging should begin within 60 ± 10
minutes. Additionally, all follow-up PET/CT studies should match the injection to
imaging time as closely as possible, varying no more than 10 minutes.

Anatomic Imaging

In addition to PET/CT imaging studies, patients also had contrast
enhanced CT studies performed. The first was collected prior to the start of
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treatment and the follow-up was collected 8 weeks after the completion of
treatment.

All images were reviewed by a board certified radiologist and

classified as representing complete, partial, stable, or progressive response [5].
The interpretation of contrast enhanced CT images was performed without
knowledge of the PET/CT results.

Post-Treatment Surveillance

Post-RT surveillance followed a well defined pathway. Initial follow-up
was scheduled for 8 weeks after the completion of treatment. Subsequently,
patients were assessed every 3 – 4 months for the first two years with clinical
examination and contrast enhanced CT studies of the head and neck. Patients
with no evidence of disease were monitored with regularly scheduled visits.

Patients with unequivocal incomplete nodal response had unilateral or
bilateral neck dissection performed.

Equivocal findings were assessed by

ultrasound-guided fine needle aspiration. Patients with negative findings were
followed with regularly scheduled visits.

Additionally, patients with positive

findings on clinical or radiographic examination for recurrent primary tumors had
salvage surgical resection performed.

Pathologic Tissue Assessment

A single board certified pathologist performed all step-sectioning and
evaluation of neck dissection samples.

This methodology is detailed in a

previous report by Moeller et al [34]. Briefly, nodes measuring greater than 1 cm
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were bisected along the longest diameter. Both halves were then sectioned with
additional levels cut at 150 μm intervals. If a node measured less than 1 cm,
one section was obtained with additional levels at 100 μm intervals. At least one
subcapsular squamous cell cluster was required for positive metastatic
involvement.

Tumor Volume Delineation

The ability to differentiate responding and non-responding primary tumors
was investigated for SUV derived in two general methods. First, the frequently
utilized SUVMax, the maximum pixel value for the most FDG-avid regions, was
collected from user defined regions that fully encompassed the most FDG-avid
tumor regions on pre-RT PET/CT images. Regions similar in size and anatomic
relation were drawn on post-RT images for post-therapeutic assessment.

Next, SUVMean was derived from three volumetric techniques. First, the
gross tumor volume (GTV) from the clinically delivered treatment plan was used
as the ROI. The GTV volume in head and neck treatments at our institution
contain both primary tumor and nodes.

However, for the purposes of this

analysis primary tumor volumes were separated from involved nodes.

GTV

contours created on planning CT images were used to collect baseline and
follow-up SUVMean. Although not created on PET images, the GTV region-ofinterest (ROI) takes advantage of the inherent registration between PET and CT
images collected with integrated scanner systems. SUV derived from this metric
represented a CT defined total tumor volume.
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Next, a volume defined exclusively on the pre-RT PET images was
utilized. The volume was defined with an auto-contouring algorithm created for
use with the Pinnacle3 treatment planning system. The source code is given in
the appendix under PET50Threshold.script.

After the PET images were

imported into the Pinnacle3 treatment planning system and assigned an
appropriate primary, CT, image set, the algorithm required the user to define a
region that fully resolved the most FDG-avid region of the image that is of
interest. This contour is denoted as “FindMaxPixel,” in the source code. Most
importantly, prior to running the script, the destination contour had the primary
volume set as the pre-RT PET image. After running the script, an isocontour
was created with the name “50Primary.” This contour encompassed all pixels in
the FDG-avid region that are 50% of the maximum pixel value or greater. This
value was selected because of its frequent use in the literature [36, 78, 79]. The
contour was then transferred to the corresponding volume on the primary image
set, in this case the pre-RT CT. This volume was then deformably mapped, as
describe above, to post-RT PET/CT images where it was used to collect the
average SUV. SUV derived from this metric represented a PET defined total
tumor volume.

Finally, SUVPeak for the FDG-avid regions at the site of the primary tumor
were determined.

SUVPeak is defined as an approximately 1 cm3 volume

centered on the maximum pixel of an FDG-avid region with a diameter of 1.2
cm. Utilizing the script SUVpeak.m, SUVpeak volumes were defined on pre-RT
PET/CT images.

The approximately 1 cm3 volume was then deformably
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mapped to post-RT PET/CT images in a procedure analogous to that described
above. SUV derived from this metric represented the most metabolically active
volume.

SUV values of responding and non-responding patients derived from
each technique were then compared. Nonparametric Mann-Whitney rank sum
tests were used to infer whether the SUV values of responding and nonresponding patients were different. Pre- and post-RT absolute SUV metrics as
well as relative change in SUV defined as,

Fractional SUV =

Post - RT SUV
Pre - RT SUV

were tested. Statistically significant differences are considered to be those with
P<0.05.

Image Registration

The alignment of tumor volumes was accomplished with two techniques.
First, pre-RT tumor volumes were mapped to serial imaging studies with an
enhanced “demons” algorithm.

Second, pre-RT volumes were registered to

serial imaging studies with rigid alignment.

The first alignment method employed a deformable image registration
technique [80, 81]. Based upon the “demons” algorithm originally proposed by
Thirion et al., it is based upon CT image intensity (Hounsfeld units)

[82].
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Intensity differences between a static and moving image are minimized
iteratively producing a displacement vector for each voxel. The displacement
vector field is then applied to the reference image, effectively deforming or
mapping voxels from the reference to the target image. Implementation of a
multi-resolution approach and the addition of an active force derived from the
intensity gradient information in the target image, have allowed the enhanced
“demons” algorithm to greatly improve the registration quality over the original
implementation. Wang et al. have shown in mathematical and phantom studies
the overall registration error of the enhanced “demons” algorithm to be
approximately 1 mm [81].

For the alternate registration technique, a CT-to-CT bony alignment
algorithm was utilized [83, 84]. By exploiting an ROI defined on the planning CT
images, the algorithm matches the same image feature in a target image set by
minimizing a cost function.

The cost function used is the mean absolute

difference in CT numbers, computed on a voxel-by-voxel basis, between the
planning and, in this case, either the pre- or post-RT PET/CT. The ROI used for
bony alignment was the C2 vertebra. The C2 vertebra was selected because of
its proximity to the multiple disease sites for the current cohort. Additionally, in
one study by Zhang et al., C2 was found to have the smallest systematic and
random daily setup variations in the anterior-posterior (AP) and superior-inferior
(SI) directions, making it a stable alignment point [85].
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Volume Alignment Workflow

The following methodology details the steps required to utilize the CT
Assisted Targeting for Radiotherapy (CAT) software to collect SUV for a volume
of interest mapped from a reference image set to a daily image set. Briefly, the
methodology involved first contouring the C2 vertebrae for each patient for initial
rigid alignment. Second, tumor volumes created within the Pinnacle Treatment
planning system and MATLAB were deformed, separately, to a daily CT image
set. For this particular project, the reference image set was the planning CT
(PCT) and the daily image sets were the pre- and post-RT PET/CT image sets.
After all contours were deformed, the SUV and dose were collected from each
volume of interest.

The output format was a text file with an (x,y,z) voxel

location within the image volume and a numeric value for the voxel (SUV or
dose). The workflow will now be explained in detail and will be of particular
interest to future investigators using the CAT software for PET/CT research.

Prior to any post-processing, all serial image sets were collected. This
was accomplished using the ClinicStation software platform.

Within this

platform, all serial studies were reviewed, selected, and then exported as
DICOM images to the internet database Evercore.

After the images were

downloaded from Evercore, folders containing the DICOM images were
renamed to CT01, CT02, PET01, or PET02 using the scanorder.m script to more
easily identify the image study chronology. While created for this specific task
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the script scanorder.m may be of use to other investigators using multiple image
sets. This script is given in the appendix.
Next, all patient treatment plans were collected. Within Philips’ Pinnacle3
Treatment Planning System (version 7.6c), the axis (C2 vertebrae) was
contoured for every patient. The axis was contoured for each patient for initial
three dimensional bone alignments.

Volumes of interest obtained from the

original treatment plan included the GTV and PET threshold algorithm. Although
not created on the planning CT images, the PET based threshold contour was
created using the Pinnacle3 treatment planning system.

Following the collection of all imaging studies and volumes of interest,
data were imported into the CAT software workspace. This includes treatment
plans and all functional imaging studies.

Within the CAT workspace, the

reference image (PCT) was first rigidly aligned to the daily image set (pre- or
post-RT PET/CT). In the case of the PET-based threshold volume the reference
image set was actually the pre-RT PET/CT image set, but the workflow was
identical.

The initial bony alignment utilized the algorithm specified in the

previous section. After a global minimum for the cost function was achieved,
translation shifts in the left/right, anterior/posterior, and superior/inferior were
applied to the volumes of interest thereby aligning them to the daily image set.
For the bony alignment arm of this aim, no further registration steps were
required and SUV was collected for pre- and post-RT PET/CT images.
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For the deformable registration arm, additional alignment steps were
required. Next, a user-defined deformation volume was selected to completely
resolve the site of primary tumor with boundaries stopping approximately
inferiorly at the level of the suprasternal notch and continuing to the most
superior slice of the PET image set. The enhanced demons algorithm was then
utilized to map all voxels within the user defined deformation volume from the
reference image set to the daily image set.

This resulted in a vector

displacement field that mapped the reference image (planning CT) separately to
the daily images (pre- and post-RT PET/CT) images. Visual inspection was
utilized to compare the daily image set with the resulting deformed reference
image set. The deformable transformations were then applied to the volumes of
interest in order to map the regions to either the pre- or post-RT PET/CT
images. Finally, SUV was collected from the serial PET/CT images using the
mapped volumes of interest.

Calculating SUV in the CAT Workspace

Tumor glucose use in this work was quantified with SUV normalized to
total body mass [86]. In order to calculate SUV, the injected dose activity in
MBq was extracted from the DICOM header and decay corrected to the time of
imaging by the following relation,

Injected DoseImaging time = Injected Dose * 0.5

Injection to imaging time
6588
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where the injected doses are in units of MBq and the denominator in the
exponent is the half life of

18

F. Next, each pixel in the image was multiplied by

the rescale slope in the DICOM header to account for the restricted maximum
pixel value of a GE PET image, 32, 7636 Bq/mL. Finally, the patient mass was
extracted and SUV was computed according to the following relation,

SUV =

Pixel value [Bq/mL] * Rescale slope * Patient mass [g]
InjectedDoseIm agingtime

Additionally, the CAT software platform capability to calculate SUV was
expanded to include lean body mass and body surface area normalization [87].

Receiver Operating Characteristic Analysis

Receiver operating characteristic (ROC) analyses were performed to
compare the ability of each metric described above to predict response to RT.
Classification of patients as normal or abnormal was based upon response to
RT as determined through pathology and continued clinical surveillance.
Median follow-up time was approximately two years post-RT. Software from
SPSS an IBM Company (Chicago, IL) was utilized to perform ROC analyses.
The ROC curve is a plot of the true positive fraction, sensitivity, versus the false
positive fraction, (1 – specificity). In other words, the sensitivity is the fraction of
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cases that a clinician calls abnormal that are actually abnormal as determined by
an alternate gold standard. The specificity is the fraction of cases that a clinician
calls normal that are actually normal. After ROC curves were created for all
SUV metrics utilized, decision thresholds were established based upon
tabulated data points of each ROC curve. The point along the ROC curve that
maximized sensitivity and minimized (1 – specificity) was selected as the
decision threshold for a particular metric.

In addition to calculating the true

positive fraction and true negative fraction for each technique (sensitivity and
specificity), positive and negative predictive values were computed (PPV and
NPN). The PPV refers to the probability that a patient is actually abnormal or a
non-responder when classified as such. On the other hand, NPV relates to the
probably that the patient is actually normal or responded to RT when classified
accordingly.

Finally, the ability of each metric to discriminate responding and nonresponding patients was compared.

The ROC curve is constructed by

determining the sensitivity and specificity at various decision threshold values.
Therefore, the area under the ROC curve (AUC) will depend upon how well the
metric is able to discriminate responding and non-responding patients and help
to quantify the usefulness of the metric. In the case of pure guessing, AUC =
0.5. If AUC is less than 0.5, the metric performs worse than guessing. Software
from MedCalc (Mariakerke, Belgium) was used to perform non-parametric tests
to compare the AUC for each metric [88]. Statistically significant differences are
considered to be those with P<0.05.
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Results:

Patient Characteristics

Following the enrollment period lasting from November 2005 through May
2007, 107 patients were screened for enrollment. 15 patients were rejected for
multiple reasons. These included: prior surgery at the site of primary tumor
(n=10), imaged off protocol (n=3), and withdrawal of consent (n=2).

This left a

total of 92 patients. Of these 22 were referred for surgical evaluation at the time
of first follow-up. Of those, 16 had no evidence of disease, responders, and 6
were found to have residual disease, non-responders. For the clinical follow-up
arm, there were 6 patients with evidence of residual disease, non-responders,
and 64 patients that responded to treatment. Because this analysis also made
use of the archived radiation treatment plan, various archiving errors further
reduced the useable population of 92, n=14.

Additionally, patients with

extreme anterior or posterior rotation of the head and neck were excluded for the
analysis because of the difficulty in registering such patients, n = 10. This left 49
responding patients and 6 non-responding.
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107 Patients screened

15 removed: consent withdrawn,
prior surgery, imaged off protocol

92 Patients

Clinical evaluation
Physical examination
Contrast enhanced CT
imaging

Surgical evaluation

22 Patients

18 Neck
dissections

2 Neck and
primary
salvage

4/20 necks
positive

70 Patients

2 Primary
salvage

4/4
primaries
positive

22 Patients
16 Responders
6 Non-responders

2 Primary
failures

4 Nodal
failures

70 Patients
64 Responders
6 Non-responders

Figure 3.1 Post Treatment Surveillance Workflow
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SUV and Treatment Response

SUV was first analyzed to determine if any associations with response to
treatment existed. Pre- and post-RT absolute SUV metrics were tested as well
as relative change in SUV. Summaries of all results are presented in table 3.1.

The SUVPeak contour was defined on pre-RT PET images as an
approximately 1 cm3 volume. This volume was then deformably mapped to the
post-RT PET/CT study.

The calculated pre-RT SUVPeak of the most

metabolically active volume of responding primary tumors was found to be 10 ±
6.7.

In non-responding patients, the pre-RT SUVPeak was 13 ± 5.0.

No

statistically significant differences were found between the SUV values in these
two groups (P> 0.05). The distribution of SUVPeak values are shown in figure
3.2a. However, statistically detectable differences were found between the postRT SUVPeak values of responding tumors (2.4 ± 0.7) and non-responding (4.6 ±
1.3) patients (P<0.01). The histogram distribution for this metric is shown in
figure 3.2b. The separation between SUVPeak values of responding and nonresponding patients is clearly visible. Additionally, the relative change between
the pre- and post-RT SUVPeak, expressed as fractional SUV was evaluated for
this ROI. No statistically discernable differences were found between fractional
SUVPeak values for responding (0.3 ± 0.2) and non-responding (0.4 ± 0.1)
patients (P>0.05). The distributions of these values are illustrated in figure 3.2c.
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a)

Figure

3.2

Deformably

aligned SUVPeak
Historgram distributions of (a)
pre- (b) post-RT , and (c)
fractional SUVPeak derived
from the 1 cm3 SUVPeak
b)

contour created on pre-RT
PET images and deformed to
post-RT

PET

images.

c)
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The SUVMax metric was evaluated next.

SUVMax, a single pixel value, is

hypothesized to represent the maximum tumor burden.

This value was

determined from a user defined volume that fully circumscribed the FDG-avid
regions. The calculated pre-RT SUVMax was found to be 19 ± 7.7 in patients
who responded to RT. In non-responding patients, the pre-RT SUVMax was 18 ±
5.9. No statistically significant differences were found between the SUV values
in these two groups (P> 0.05). The distribution of pre-RT SUVMax values are
shown in figure 3.3a. However, statistically detectable differences were found
between the post-RT SUVMax values of responding tumors (4.5 ± 1.3) and nonresponding (6.7 ± 2.0) patients (P<0.01). The histogram distribution for this
metric is shown in figure 3.3b.

The separation between SUVMax values of

responding and non-responding patients is clearly visible, yet not as pronounced
as seen for the SUVPeak contour. The relative change between the pre- and
post-RT SUVMax, was found to be statistically significant (P<0.05).

The

distribution of fractional SUVPeak for responding (0.3 ± 0.2) and non-responding
(0.4

±

0.2)

patients

is

shown

in

figure

3.3c.
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Figure 3.3 SUVMax

a)

histograms

Histogram distributions of (a)
pre- (b) post-RT, and (c)
fractional

SUVMax

derived

from a user defined region
that fully resolved the FDG
avid region.
b)

c)
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The 50% isocontour volume was defined on pre-RT PET images and
encompassed all pixels in the FDG-avid volume that were within 50% of the
maximum pixel value. This volume was then mapped to the post-RT PET/CT
study. The calculated pre-RT SUV for the threshold PET-based contour was
found to be 11 ± 5.1.

In non-responding patients, SUVMean for the 50%

isocontour was 11 ± 5.9.

No statistically significant differences were found

between the SUVMean values in these two groups (P> 0.05). The distribution of
SUVMean values for the threshold ROI are shown in figure 3.4a. However,
statistically detectable differences were found between the post-RT SUVMean
values of responding tumors (2.8 ± 0.5) and non-responding (3.4 ± 0.7) patients
(P<0.05).

The histogram distribution for this metric is shown in figure 3.4b.

Finally, the relative change between the pre- and post-RT SUVMean for this
ROI, expressed as fractional SUV was evaluated. No statistically discernable
differences were found between responding fractional SUVMean (0.3 ± 0.2) and
non-responding (0.4 ± 0.2) fractional SUVMean at the 95% confidence level.
The distributions of these values are illustrated in figure 3.4c.
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a)
Figure 3.4 Deformably
aligned PET-based threshold
contour

Historgram distributions of (a)
pre- (b) post-RT , and (c)
fractional SUVMean derived from
b)

deformably mapped threshold
contour that encompasses all
pixels within 50% of SUVMax.

c)
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The final contour to be evaluated was the CT-based GTV. The GTV
contours created for this study were created on planning CT images and then
mapped separately to pre- and post-RT PET/CT images, where they were
utilized as ROIs to determine SUV. The calculated pre-RT SUV for the gross
tumor volume of patients who ultimately responded to treatment was 6.7 ± 3.3.
In non-responding patients, the pre-RT SUV was 5.8 ± 2.1.

No statistically

significant differences were found between the SUV values in these two groups
(P> 0.05).

The distribution of SUVMean values derived for the total tumor

volume is shown in figure 3.5a. However, statistically detectable differences
were found between the post-RT SUV values of responding tumors (2.6 ± 0.4)
and non-responding (3.2 ± 0.7) patients (P<0.05). The histogram distribution for
this metric is shown in figure 3.5b. The separation between SUVMean values of
responding and non-responding patients is clearly visible, but marked overlap
between the two groups is seen. Additionally, the relative change between the
pre- and post-RT SUV, expressed as fractional SUV was evaluated for this ROI.
No statistically discernable differences were found between responding
fractional SUVPeak (0.5 ± 0.3) and non-responding (0.6 ± 0.2) at the 95%
confidence level. The distributions of these values are illustrated in figure 3.5c.
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a)
Figure 3.5 Deformably
aligned GTV contour

Historgram distributions of (a)
pre- (b) post-RT , and (c)
fractional
from
b)

created
images

SUVMean

the

GTV

on

derived
contour

planning

and

CT

deformably

mapped to pre- and post-RT
PET/CT images.

c)

46

Responder

Non-responder

Pre-RT

PostRT

Fractional
SUV

Pre-RT

PostRT

Fractional
SUV

SUVMax

19 ± 7.7

4.5 ±1.3

0.3 ± 0.2

18 ± 5.9

6.7 ± 2.0

0.4 ± 0.2

SUVPeak

10 ± 6.7

2.4 ± 0.7

0.3 ± 0.2

13 ± 5.0

4.6 ± 1.3

0.4 ± 0.1

50%
Isocontour

11 ± 5.1

2.8 ± 0.5

0.3 ± 0.2

11 ± 3.9

3.4 ± 0.7

0.4 ± 0.2

GTV primary

6.7 ± 3.3

2.6 ± 0.4

0.5 ± 0.3

5.8 ± 2.1

3.2 ± 0.7

0.6 ± 0.2

Background

4.9 ± 1.0

4.6 ± 1.0

0.9 ± 0.2

4.3 ± 1.1

4.0 ± 1.0

0.9 ± 0.3

Table 3.1 Average SUV values derived from deformably mapped volumes
for responding and non-responding patients.

Tabulated here are absolute and fractional SUV metrics for the cohort stratified
by primary tumor response. One standard deviation is presented along with
each mean value. Statistically discernable differences between responding and
non-responding patients are shown in bold face type (P<0.05).
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Predicting RT Outcomes with SUV

Absolute post-RT SUV was identified as the superior metric to
differentiate patients responding to RT from those who did not. Next, post-RT
SUV decision thresholds were determined for each technique based upon
tabulated data from each ROC curve. In figure 3.6, the ROC curves for post-RT
SUV from each technique are shown. For reference, the curve representing
performance of pure guessing is plotted as a dashed line.

Additionally, the

sensitivity and (1 – Specificity) for the post-RT contrast enhanced CT is shown
as a single data point for comparison. The binary end point, response to RT,
was defined as a reading of complete radiographic response.
radiographic endpoints:

All other

partial response, stable disease, and progressive

disease were defined as non-responders. Post-RT contrast enhanced CT was
found to have a sensitivity of 80% and a specificity of 92%.

Radiographic

analysis yielded one false positive. Overall, CT had a positive predicted value of
50%.

Decision thresholds that maximize sensitivity and minimize (1 –
specificity) for each technique were selected from tabulated ROC curves. For
the SUVMax metric, a post-RT absolute SUV decision threshold value of 6.4 was
selected. Based upon this cutoff, sensitivity (80%) and specificity (94%) were
calculated. This cutoff point led to one false negative. The positive predictive
value of post-RT SUVMax was calculated to be 57%. This result is slightly better
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than what was found for contrast enhanced CT and notable for performing better
than guessing.

The best performing technique was the SUVPeak metric. A post-RT SUV
decision threshold of 3.5 was selected from the tabulated ROC analysis. This
cutoff point yielded the highest sensitivity of any method, 100%, and a very high
specificity, 94%.

Notably, this was the only technique to have zero false

positives. The positive predictive value was 63% and the negative predictive
value was 100%, the highest values for all techniques investigated.

The 50% threshold and GTV contour both performed poorly. For the
PET-based threshold contour, a decision threshold of 3.3 was selected. Utilizing
this cutoff, the sensitivity was found to be no better than contrast enhanced CT,
80%, and the specificity was found to be worse, 88%. Similar to CT evaluation,
this analysis resulted in one false negative. While the negative predictive value
was high, 98%, the positive predictive value was less than 50%. Results for
SUVMean derived from the mapped GTV contour were similar.
threshold of 2.8 was identified.

A decision

This resulted in one false negative.

The

sensitivity was identical to all other techniques, aside from SUVPeak, but
ultimately proved to have the worst specificity, 69%. Furthermore, the positive
predictive value of this technique was the lowest at 21%. Table 3.2 displays the
results of all ROC analyses.

The SUVPeak method resulted in the largest area under the ROC curve,
0.98 (0.89 – 0.99, 95% C.I.). Both SUVMax and SUVMean derived from the 50%
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threshold contour had areas of 0.93 (0.82 – 0.98 95% C.I.). Finally, SUVMean
determined for the GTV volume had the smallest area, 0.8 (0.67 – 0.90 95%
C.I.). First, consider the SUVPeak metric that resulted in the highest positive and
negative predictive values. Statistically significant differences in the area under
the ROC curve were found between the SUVPeak metric and SUVMean derived
from the GTV contour (P<0.05).

No statistically significant differences were

found between the area under the SUVPeak curve and the area under the curves
of all other metrics (P> 0.05). Pair-wise comparisons between all other metrics
found no significant differences in the area under each curve (P>0.05).
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Figure 3.6 ROC curves for the deformably aligned volumes

ROC curves for SUVMax and SUVMean derived from the GTV contoured on
planning CT images and a PET-based 50% threshold contour and SUVPeak are
shown.

The single data point represents the sensitivity and specificity of

contrast-enhanced CT for the study.
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CT
Decision threshold
True positives
False negatives
True negatives
False positives
Sensitivity
Specificity
Positive predictive value
Negative predictive value

4
1
45
4
0.80
0.92
0.50
0.98

SUVMax SUVPeak 50% Isocontour GTV Primary
6.4
3.3
2.8
3.5
4
4
4
5
1
1
1
0
46
43
34
46
3
6
15
3
0.80
0.80
0.80
1.00
0.94
0.88
0.69
0.94
0.57
0.40
0.21
0.63
0.98
0.98
0.97
1.00

Table 3.2 Accuracy of response prediction with deformably mapped
volumes

Cutoff values were selected from ROC curves to classify patients as normal or
abnormal.

The raw numbers for each error type are tabulated along with

calculated sensitivity, specificity, positive predictive values, and negative
predictive values. The superior metric is denoted in bold face type.
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Correlating SUV Derived from Bony Alignment Contours to Treatment
Response

While the first major arm of this aim investigated the ability of SUV
derived from mapped contours to assess and predict response to RT, the
second arm investigated the impact of improved registration on treatment
response monitoring. For the second major arm of this specific aim, SUV was
derived from pre-treatment volumes aligned to the C2 vertebra on pre- and postRT PET/CT images. Pre- and post-RT absolute SUV metrics, as well as relative
change in SUV, derived from the rigidly aligned contours were analyzed for
correlations to response to RT. Summaries of all results are presented in table
3.3.

Post-RT absolute SUVPeak derived from contours mapped to pre- and
post-RT PET/CT studies was the best performing metric in the previous
analysis. The calculated pre-RT SUV of the most metabolically active volume of
responding primary tumors was found to be 10 ± 6.7.

In non-responding

patients, the pre-RT SUVPeak was 13 ± 5.0. These values are identical to those
from the previous section as this contour is defined on pre-RT PET/CT images.
Therefore, no statistically significant differences were found between the SUV
values in these two groups (P> 0.05) as discussed above.

Contrary to the

previous SUVPeak results, statistically detectable differences were not found
between the post-RT SUVPeak values of responding tumors (2.6 ± 0.6) and nonresponding (2.8 ± 0.8) patients (P>0.05). The histogram distribution for this
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metric is shown in figure 3.7b. For comparison, the histogram distribution for the
deformably mapped SUVPeak volume is shown in figure 3.7a. It is clear from the
distributions that bony alignment of the pre-RT SUVPeak volume was not
sufficient to capture the FDG-avidity of the residual tumor. Additionally, the
relative change between the pre- and post-RT SUVPeak, expressed as fractional
SUV was evaluated for this ROI.

Once again no statistically discernable

differences were found between responding fractional SUVPeak (0.4 ± 0.4) and
non-responding (0.3 ± 0.1) (P>0.05).

The PET-based threshold contour was analyzed next. The calculated pre-RT
SUV for the threshold PET-based contour was found to be 11 ± 5.1. In nonresponding patients, SUVMean for the 50% isocontour was 11 ± 3.9.

As

mentioned above, these volumes are defined on the pre-RT PET/CT images and
the results of the previous analysis will not alter in the present scenario. In
contrast to the analyses with deformed contours, statistically detectable
differences were not found between the post-RT SUVMean values of responding
tumors (2.0 ± 0.4) and non-responding (2.1 ± 0.3) patients (P>0.05).

The

histogram distribution for this metric is shown in figure 3.8b. In figure 3.8a, the
distribution of SUVMean derived from the mapped threshold contour is shown for
reference. Of note is the shift toward lower SUV values for the rigidly aligned
contours, indicating incomplete resolution of the FDG-avid volume. Finally, the
relative change between the pre- and post-RT SUVMean for this ROI, expressed
as fractional SUV was evaluated. No statistically discernable differences were
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a)

b)

Figure 3.7 Bony and deformed SUVPeak distributions
Histogram distributions for deformably (a) and rigidly (b) aligned PET-based
SUVPeak contour.
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found between responding fractional SUVMean, 02 ± 0.1, and non-responding, 0.2
± 0.1, fractional SUVMean, P>0.05.
The final contour to be evaluated was the bony aligned CT-based GTV.
The calculated pre-RT SUV for the gross tumor volume of patients who
ultimately responded to treatment was 3.5 ± 1.3. In non-responding patients, the
pre-RT SUV was 5.6 ± 2.5. No statistically significant differences were found
between the SUV values in these two groups (P> 0.05). As seen for all rigidly
aligned contours, no statistically detectable differences were found between the
post-RT SUV values of responding tumors (1.9 ± 0.3) and non-responding (2.1 ±
0.3) patients (P>0.05). The histogram distribution for this metric is shown in
figure 3.9b.

Additionally, the relative change between the pre- and post-RT

SUV, expressed as fractional SUV was evaluated for this ROI. No statistically
discernable differences were found between responding fractional SUVPeak (0.6
± 0.2) and non-responding (0.5 ± 0.3) (P>0.05).
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a)

b)

Figure 3.8 Bony and deformed PET threshold contour

Histogram distributions for deformably (a) and rigidly (b) aligned PET-based
50% threshold contour.
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a)

b)

Figure 3.9 Bony and deformed GTV

Historgram distributions for deformably (a) and rigidly (b) aligned CT-based GTV
contour.
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Responder

SUVPeak
50%
Isocontour
GTV
primary

Non-responder

PreRT

PostRT

Fractional
SUV

PreRT

PostRT

Fractional
SUV

10 6.7

2.6 0.6

0.4 04.

13 5.0

2.8 0.8

0.3 0.1

11 5.1

2.0 0.4

0.2 0.1

11 3.9

2.1 0.3

0.2 0.1

3.5 1.3

1.9 0.3

0.6 0.2

5.6 2.5

2.1 0.3

0.5 0.3

Table 3.3 Average SUV values for responding and non-responding patients
from rigidly aligned volumes.

Tabulated here are absolute and fractional SUV metrics derived from rigidly
aligned ROIs for the cohort stratified by primary tumor response. One standard
deviation is presented along with each mean value. No statistically discernable
differences were found between SUV values of responding and non-responding
patients (P<0.05).
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Predicting RT Outcomes with SUV Derived From Bony Aligned Volumes

In contrast to the excellent ability of SUV derived from deformably
mapped contours to distinguish responding from non-responding patients, the
bony aligned pre-RT volumes overall performed poorly. In the previous ROC
analyses, only those metrics that could significantly differentiate responding from
non-responding patients were utilized. In the current analysis, no rigidly aligned
metrics met this benchmark. In figure 3.10, the ROC curves for post-RT SUV
from each technique are shown.

For reference, the curve representing

performance of pure guessing is plotted as a dashed line.

Additionally, the

sensitivity and (1 – Specificity) for the post-RT contrast enhanced CT is shown
as a single data point for comparison. The post-RT contrast enhanced CT was
found to have a sensitivity of 80% and a specificity of 92%.

Decision thresholds that maximize sensitivity and minimize (1 –
specificity) for each technique were selected from tabulated ROC curves. For
the SUVPeak metric, a post-RT SUV decision threshold of 3.1 was selected from
the tabulated ROC analysis. This cutoff point yielded the highest sensitivity of,
100%, and specificity, 94%, for the deformably mapped contours. However, for
the rigidly aligned volumes the sensitivity (60%) and specificity (78%) were
lower. The decision threshold resulted in 2 false negatives in comparison to
zero for the deformed contours. The positive predictive value was 21% and the
negative predictive value was 95%. These values were lower than for contrast
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enhanced CT, but the positive predictive value was the best for the rigidly
aligned PET metrics.

The 50% threshold and GTV contour both performed poorly. For the
PET-based threshold contour, a decision threshold of 2.0 was selected. Utilizing
this cutoff, the sensitivity was found to be no better than the rigidly aligned
SUVPeak, 60%, and the specificity was found to be worse, 61%.

One false

negative was identified. While the negative predictive value was high, 94%, the
positive predictive value was the lowest found, 14%.

Results for SUVMean

derived from the rigidly aligned GTV contour were similar. A decision threshold
of 1.9 was selected. This resulted in one false negative. The sensitivity was
better than all other techniques and identical to contrast enhanced CT, 80%.
The specificity was 63%.

Furthermore, the positive predictive value of this

technique was the second lowest at 18%. Table 3.4 displays the results of all
ROC

analyses.
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Figure 3.10 ROC curves for rigidly aligned volumes

ROC curves for SUVMean derived from the rigidly aligned GTV, PET-based
50% threshold contour, and SUVPeak are shown.

The single data point

represents the sensitivity and specificity of contrast-enhanced CT for the study.
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Cutoff value
True positives
False negatives
True negatives
False positives
Sensitivity
Specificity
Positive predictive
value
Negative predictive
value

CT

SUVPeak

4
1
45
4
0.80
0.92

3.1
3
2
38
11
0.60
0.78

50%
Isocontour
2.0
3
2
30
19
0.60
0.61

0.50

0.21

0.14

0.18

0.98

0.95

0.94

0.97

GTV Primary
1.97
4
1
31
18
0.80
0.63

Table 3.4 Accuracy of response prediction with rigidly aligned volumes

Cutoff values were selected from ROC curves to classify patients as normal or
abnormal.

The raw numbers for each error type are tabulated along with

calculated sensitivity, specificity, positive predictive values, and negative
predictive values.
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Comparing SUV Derived from Bony and Deformable Alignment

To compare the performance of each technique, the area under each
curve of the ROC plot was compared pair-wise. SUVMean derived from the GTV
contour resulted in the largest area under the ROC curve, 0.73 (0.55 – 0.90,
95% C.I.). This is in contrast to what was found with the deformably mapped
contours, where the GTV contour had the smallest area under the ROC curve.
SUVMean derived from the 50% threshold contour had an area of 0.56 (0.34 –
0.79 95% C.I.). Finally, SUVPeak was found to have an area under the ROC
curve equal to 0.62 (0.31 – 0.92 95% C.I.). Comparison of the area under the
ROC curves for each rigidly aligned contour found no statistically significant
differences (P>0.05).

However, when comparing the rigidly aligned contour to the deformably
mapped contours the results are markedly different. First, consider the SUVPeak
metric. The difference between the areas under each ROC curve was found to
be 0.37 (0.04 – 0.71 95% C.I.).

Deformably mapping the SUVPeak volume

defined on pre-RT PET/CT images to post-RT images was found to significantly
increase the area under the ROC curve (P<0.05) when compared to bony
alignment of this volume.

Next, consider the 50% threshold contour.

The

difference in AUC was between the two alignment techniques was found to be
0.37 (0.14 – 0.59 95% C.I.). This increase in AUC is significant at the 95%
confidence level. Finally, consider the only contour created on CT images, the
GTV. The difference in AUC between the two alignment methods was 0.07 (-
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0.07 – 0.22 95% C.I.). This increase in AUC was not significant (P>0.05). On
the whole, deformable mapping of pre-RT volumes to determine SUV increased
the ability of PET/CT to predict response to RT for this data set.

Discussion:

Many studies assessing and predicting response to RT with
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PET/CT have reported positive outcomes for patients that showed reduced FDG
uptake [89-93].

Quantification of residual disease and subclinical response

offers the possibility to obtain a detailed picture of tumor viability and has been
sought for some time [94].

Recent studies have confirmed the ability of

quantitative PET/CT to distinguish residual disease, but with little benefit over
conventional imaging [34]. Limited usefulness of the modality may be related to
tumor sampling and recent position papers have suggested that response
analyses should move away from the traditionally used single pixel values to
region based assessment [95].

However, the presence of gross anatomical

changes and multiple imaging studies will require accurate localization of FDGavid volumes.

The appropriate volume to derive SUV from is a complex question. Total
tumor volume was investigated and defined on CT and PET images.

One

potential benefit of using a larger volume is that they tend to have less variability
in SUV than smaller ones [96]. This concept was reinforced by the bony aligned
GTV ROC curve. The GTV contour had the largest AUC most likely due to the
large volume of tissue contained within, making it less susceptible to incomplete
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resolution of the most FDG-avid region.

The GTV contour created on the

planning CT images was the only metric not able to differentiate the SUV of
responding and non-responding patients when deformably mapped to pre- and
post-RT images.

This may have resulted from the larger volume used to

determine SUV (33 cm3 vs. 1 cm3) that included necrotic as well as residual
cancer cells.

Additionally, because the GTV was defined on CT images,

misalignment between the inherently aligned PET and CT images could result in
calculating SUV for undesired tissue. In one study, misalignment in head and
neck PET/CT was found to be as much as 1o or 7 mm [97].

The most widely used, and smallest relative volume, has been SUVMax.
The maximum pixel value has been used to assess potential residual disease
because it was thought to represent the maximum tumor burden, although it may
just represent the most convenient metric.

This metric is also known to be

greatly affected by image noise and may not be the ideal metric [96].
Alternatively, SUVPeak has begun to gain favor [95]. One potential drawback of
the SUVPeak method would be a non-centrally located maximum pixel. In this
case, the 1 cm3 could potentially include adjacent normal tissue. This scenario
could be quite troubling for tumors with maximal dimensions less than 1.2 cm.
The average lesion size for the cohort as measured on pre-RT CT was 2.7 cm.
Lesions less than 1.2 cm did not have SUVPeak determined in this study. The
average largest diameter measureable on post-RT CT was 2.9 cm.
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For the current cohort, SUVPeak of non-responding patients was
significantly higher than patients who responded to treatment (4.6 ± 1.3 vs. 2.4 ±
0.7, P<0.01) when derived from the deformably mapped volume.

After a

decision threshold was selected, SUVPeak was the only method to have zero
false negatives. Additionally, the PPV for residual disease was 63%. For postRT contrast enhanced CT, PPV was only 50%. Because SUVPeak is centered on
the most metabolically active region of a tumor, viable residual cancer cells are
likely to be circumscribed by this volume [98-100].

Assessing response to

treatment based upon FDG-uptake in the total tumor volume may reduce the
post-RT SUV and mask the metabolic activity in this more critically important
tumor region.

Although significant differences were found between absolute post-RT
SUV values of responding and non-responding patients this separation may be
artificial.

The SUV value can be affected by many factors including patient

preparation, incorrect cross-calibration of scanner and dose calibrator, and
variable injection to imaging times [101]. Assessing the SUV of background
tissue can be a powerful discriminator in determining if differences between two
patient groups are real. The liver has been suggested as a stable background
measurement point, but all patients in this cohort were head and neck cancer
patients and PET/CT images did not include the liver [95]. Alternatively, nonvisual cortex brain tissue was shown in one study to function well as a
background measurement point [102].

The brainstem was selected as a

background measurement point because it is often contoured in head and neck
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treatment planning. Post-RT SUVMean for the brainstem in the responding group
(4.7 ± 1.1) and non-responding group (3.9 ± 1.0) were not significantly different
(P>0.05).

This strengthens the case for SUV differences between the two

patient groups representing real effects.

When comparing the deformably aligned volumes to the alternate
alignment to a bony structure the advantage was clear. The alternative method
of alignment was based upon registration to the C2 vertebra.

For all volumes

considered, SUV derived from bony aligned volumes was not significantly
different

between

responding

and

non-responding

patients

(P>0.05).

Additionally, the use of deformably mapped volumes was found to significantly
increase the AUC for the SUVPeak volume and the threshold contour ROC
curves, but not for the CT-based GTV.

Conclusions:

In conclusion, deformable image registration was found to improve region
based response analysis. Specifically, for the most metabolically active tumor
regions, mapping this volume across longitudinal studies significantly improved
the predictive power of PET/CT over bony alignment (P<0.05). A post-RT SUV
decision threshold of 3.5 was selected for SUVPeak. Utilizing this cutoff, the PPV
for PET/CT was 63%, markedly higher than post-RT contrast enhanced CT
(50%). However, because the number of non-responding patients was small (n
= 6), the results of the study need validation. The results of this aim support the
hypothesis that voxel-by-voxel mapping of primary tumor volumes to serial F-
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FDG PET/CT images would improve region based response analysis.
Incorporating deformable image registration into quantitative treatment response
monitoring studies to more accurately localize residual disease may greatly
impact patient management and allow for more timely intervention.
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Chapter 4

Specific Aim 2a

Evaluate the potential to determine normal organ-at-risk (OAR) toxicity in
patients treated with intensity modulated radiotherapy (IMRT) for head and neck
cancers with 18F-FDG PET/CT.

.

Working Hypothesis: Parotid gland SUV will function as an objective
imaging biomarker of salivary toxicity correlating with stimulated salivary
flow (P<0.05).

Purpose

As described in Chapter 2, current methods used to assess salivary
toxicity in patients treated for head and neck cancers with RT are limited and
perform poorly. For instance, for the cohort employed in specific aim 1 only
30/107 screened patients had any measure of salivary toxicity collected as part
of the routine standard of care. When salivary toxicity measures were collected,
they were limited to xerostomia questionnaires only collected after RT. Without
baseline measures, assessing the toxicity of a treatment is particularly
challenging.

The potential of imaging biomarkers to measure the effects of cancer
treatments have been well documented [92, 103, 104]. Arming clinicians with an
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in vivo continuous variable that functions as a surrogate for clinical endpoints
has powerful implications for patient management. Yet, relatively little attention
has been paid to investigating the ability of imaging biomarkers to quantify
normal organ-at-risk (OAR) toxicity [105-107]. The near drought of work in this
area has lead to the establishment of groups like the Image Response
Assessment Team (IRAT) whose sole purpose is to further the use of
quantitative imaging for treatment response to therapy in the clinic. Additionally,
recent changes in reimbursement guidelines for PET from the Centers of
Medicare and Medicaid will only increase the number of number of initial staging
and follow-up PET scans being performed [108].

Because of the expanding role of PET/CT in patient management the
opportunity exists for uses tangential to initial staging or follow-up. Specifically,
for patients with head and neck cancer, incidental collection of parotid
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uptake was investigated as a surrogate for salivary function. Sialometric data
collected on the same day as PET/CT imaging studies were correlated with SUV
determined for the parotid glands in this study. Utilization of imaging biomarkers
in this manner may allow for patient specific refinement of radiation treatment
plans to reduce normal OAR toxicity.
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Methods and Materials

Patient Cohort

To test the working hypothesis for specific aim 2, a separate cohort was
employed in which patients had pre- and post-RT PET/CT imaging and
measures of salivary function collected at the same time point. Patients were
selected from an ongoing IRB approved protocol (LAB07-0050) designed to
establish a database of the effects of RT on salivary flow. Inclusion criteria
included patients with histological conformation of head and neck cancer set to
receive definitive RT, concurrent chemotherapy, or RT after surgery who were at
least 18 years of age. Patients who had previous RT of the head and neck were
excluded. Sialometric as well as subjective measures of salivary toxicity were
collected at five time points.

The first collection was prior to the start of

treatment. While only a snapshot of salivary gland function, this time point will
serve as the baseline measurement for saliva production. The second time
point is following RT, approximately 6 weeks. The third time point is at four to
six months after the completion of RT. The fourth collection date is at one year
post-RT (± 2 months). Finally, the last collection time point is two years after the
completion of treatment (± 3 months).

Sialometric Evaluation

Whole mouth stimulated and unstimulated saliva was collected at each
time point. For the unstimulated collection, patients were instructed to refrain
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from eating, drinking, or dental hygiene for at least 30 minutes. The goal was to
minimize the impact of all oral stimuli. The subject was instructed not to induce
salivation.

Each collection period lasted five minutes; this was shown on a

digital timer in view of the patient. During collection patients were instructed not
to swallow and let the saliva accumulate in the floor of the mouth. Every sixty
seconds the patient was instructed to expectorate the accumulated saliva into
100 mL vials. This procedure was repeated every minute for the five minute
collection period. Each empty vial was massed prior to saliva collection. After
the patient’s saliva was collected the vial and saliva were massed.

The

difference between the two measurements is the mass of the saliva.

In order to measure the stimulated whole mouth saliva, the patient was
instructed to rest for five minutes after the collection of unstimulated whole
mouth saliva. To induce salivation, 20 mL of a citric acid solution was held in the
patient’s mouth for one minute.

The same methodology described for the

unstimulated salivary collection was employed to collect stimulated salivary
mass.

For each patient stimulated and unstimulated baseline salivary flow
measurements were assessed for abnormality.

Unstimulated whole salivary

flow rates less than 0.1 mL/min and stimulated whole salivary flow rates less
than 0.5 mL/min have historically been labeled as abnormal [109]. The salivary
flow thresholds for abnormal flow were converted to mass cutoffs for the
collection period of five minutes utilized in this protocol. For the unstimulated
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sialometric data, whole mouth salivary mass less than 0.5 g was classified as
abnormal. For the stimulated salivary data, whole mouth salivary mass less
than 2.5 g was defined as abnormal baseline salivary function.

Subjective Evaluation

Patient

self-reported

xerostomia

questionnaires

were

utilized

for

subjective evaluation of salivary toxicity [75]. The patient completed a set of
eight questions on the degree of difficulty talking, chewing, and swallowing due
to perceived dryness. Each question received a score of 1 – 10, with greater
numerical value corresponding to greater perceived complication.

Finally, a

summary score was created by summing the results of each question to produce
a value between 0 and 80.

Xerostomia Grade

Salivary toxicity was assessed using the EORTC/RTOG late effects
toxicity scoring subjective, objective, management, analytic (SOMA) scale. The
analytic scale was employed to classify patients into grade 0 – 4 xerostomia at
the time of first follow-up (approximately 50 days post RT). The analytic scale
separates patients into grades by assessing the saliva produced as compared to
baseline. The percentages are presented in table 4.1.
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Salivary
flow/quantity

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

> 95% of pretreatment

76% - 95%
of pretreatment

51% - 75%
of pretreatment

26% - 50%
of pretreatment

0% - 25%
of pretreatment

Table 4.1 RTOG/EORTC late effects analytic scale

Salivary toxicity grades are defined by the relative change in saliva production.
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Volume Delineation

In order to evaluate the potential of using SUV as an objective imaging
biomarker of salivary function, physician created parotid contours created on
planning CT images were utilized. The general delineation guidelines for the
human parotid glands follow specific anatomical landmarks [110]. The superior
boundary extends to the external auditory canal and mastoid process, figure
4.1a. Inferiorly, the parotids were contoured to the submandibular space, figure
4.1b. In the anterior direction, masseter muscle forms the boundary. This is
shown in figure 4.1c.

The sternocleidomastoid muscle forms the posterior

border. Laterally, the parotids are bounded by subcutaneous fat. Finally, the
medial border is formed by the posterior belly of the digastric muscle.

However, these are only guidelines.

For instance, in 20% of the cases,

the parotid will extend anteriorly past the masseter muscle [111]. Other, nonpatient, variations will also exist in the parotid contours.

For example, the

adaptive protocol cohort had contour created by multiple physicians (n = 7). In
a 2005 study of the inter-observer contouring variations for head and neck
anatomy, it was found that when compared to a mixed volunteer cohort ,
experienced head and neck radiation oncology specialist were able to reduce
volume coefficient of variation (defined as the quotient of the standard deviation
and the mean volume) by 16% for the parotid glands. The presence of dental
artifacts only impacted the contour volume coefficient of variation by 6%. The
center-of-volume standard deviation was reduced to 1 mm [112].

These
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variations were found to be acceptable.

It is understood that while both

anatomical and observer variations exist in the parotid contours, this is not
expected to fundamentally alter the conclusions of the technique.

The parotid glands were originally contoured on planning CT images
collected for patient simulation. These physician created volumes were then
deformably mapped to the pre- and post-RT PET/CT images using the
enhanced demons algorithm and the same methodology described for specific
aim 1.

In figure 4.2, an example patient’s pre-RT PET/CT with deformably

aligned parotid contours is shown. In figure 4.2b and 4.2d, FDG-avid parotid
glands are shown before and after RT, respectively. The PET image has the
upper window level set to the maximum SUV value within the parotids with the
lower window set at 42% of this value [113].
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a)

b)

c)

d)
Figure 4.1 Parotid anatomical boundaries

The anatomical structures that form the common boundaries for the parotid
glands (orange) are depicted in each frame (white arrow). The submandibular
glands are shown in purple. (a) The external auditory canal forms the superior
boundary of the parotid glands. The inferior boundary is formed by the
submandibular space (b). In (c), the masseter muscle forms the anterior
boundary with the sternocleidomastoid muscle forming the posterior border. The
platysma forms the lateral border (d) while the posterior belly of the digastric
muscle forms the medial border.
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a)a)

c)
c)

b)b)

d)
d)
Figure 4.2

Pre-RT CT (a) and PET (b) co-registered images with deformably aligned
parotid contours (purple). The green contour denotes the skin surface. The
post-RT CT (c) and PET (d) are also shown.
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Results:

Patient Characteristics

Fourteen patients were available for the current analysis that had preand post-RT PET/CT as well as salivary evaluation performed. The cohort was
composed mostly of males, n = 12, and few females, n = 2. The average age of
the group was 57 years with a range of 49 – 75 years. Normal variations in
saliva production have been shown to be age and gender independent [114,
115].

Tumor staging was based upon the American Joint Committee on
Cancer. Nine patients had stage four, three patients had stage three, and one
patient each had stage one or two disease. All primary tumors were located in
the oropharynx. The prescription dose was 70 Gy, n = 12, and 66 Gy, n = 2.
Patients were treated once daily with a fraction size of 2.0 Gy, n = 4, 2.12 Gy, n
= 8, or 2.2 Gy, n = 2. The mean dose delivered to the parotid glands was 28 ± 6
Gy. The ipsilateral parotid gland, defined as the most proximal of the paired
glands to the primary tumor, received mean doses of 36 ± 12 Gy.

The

contralateral parotid gland received considerably lower mean doses of 20 ± 2
Gy.

Baseline Saliva Output

Measurements of baseline salivary flow were used to establish patients
with pre-existing abnormal salivary function. For the fourteen accrued patients,
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unstimulated saliva production for a five minute collection period had an average
value of 1.92 ± 1.04 g with a range of 0.45 – 4.04 g. The distribution of baseline
unstimulated flow is illustrated in figure 4.3. Utilizing the specified cutoff for
abnormal salivary function, for unstimulated salivary flow, 0.5 g, one patient was
identified as having abnormal baseline function. The vertical reference line in
figure 4.3 depicts this cutoff.

For the baseline stimulated saliva production, an average mass of 5.51 ±
2.4 g was found with a range of 1.51 – 9.46 ). The histogram in figure 4.4
graphically displays the distribution of baseline stimulated saliva production.
The cutoff for abnormal baseline stimulated whole mouth salivary flow, 2.5 g,
identified one additional patient.

Furthermore, because xerostomia is

fundamentally a subjective disorder, baseline XQL questionnaire scores were
utilized to identify patients who believed their function was abnormal.

Two

patients were found with XQL summary scores above the 40 threshold. These
data are illustrated in figure 4.5.

The scale XQL scale (0 – 80) has been

truncated in the figure.

In summary, 4/14 patients were identified as having abnormal baseline
salivary function through objective and subjective measures.

The average

unstimulated saliva mass in the abnormal baseline function group was 1.67 ±
0.89 g. The range of salivary mass was 0.67 – 2.84 g. The normal baseline
function group had an average unstimulated saliva mass of 2.02 ± 1.12 g with a
range of 0.45 – 4.04 g. There was no significant difference found between the
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two groups (P>0.05). Even when the two patients classified as abnormal based
upon baseline XQL summary scores were not considered, the unstimulated
saliva mass was not significantly greater in the “normal” group.

For the

simulated salivary flow, the abnormal baseline function group produced an
average of 4.32 ± 2.97 g with a range of 1.51 – 7.80 g. The normal baseline
stimulated flow group produced an average saliva mass of 5.98 ± 2.19 g. The
range of saliva mass values was 3.12 – 9.46 g. No significant difference was
found between the stimulated saliva mass of normal and abnormal baseline
salivary function patients (P>0.05).

However, if the patients classified as

abnormal based upon XQL summary scores are not considered the stimulated
saliva mass for the normal function group is significantly greater than the
abnormal function group, 1.9 ± 0.5 vs. 6.1 ± 1.1 P<0.05.
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Figure 4.3 Baseline salivary mass

Unstimulated salivary mass collected prior to treatment.

The vertical line

represents the cutoff for “abnormal” function.
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Figure 4.4 Baseline salivary mass

Stimulated salivary mass collected prior to treatment.

The vertical line

represents the cutoff for “abnormal” function.
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Figure 4.5 Patient perceived baseline salivary function

XQL summary score distribution prior to treatment. The vertical line represents
the median of the scale.

Note XQL scale (0 – 80) is truncated for display

purposes.
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Correlating Baseline Salivary Function and SUV

Following the deformation of all physician contoured pre-RT parotid
volumes to the pre-RT PET/CT images, SUV was determined for the parotid
glands. Parotid gland pre-RT SUV for the baseline abnormal patients was found
to be (1.2 ± 0.2), n = 4. For the normal baseline salivary function patients,
parotid gland pre-RT SUV was found to be (1.6 ± 0.3), n = 10. This difference in
SUV between the normal and abnormal baseline salivary function patients was
significant (P<0.05). This was in contrast to the insignificant differences of the
stimulated and unstimulated saliva mass between the two patient groups. The
distribution of pre-RT SUV is shown in figure 4.6.

Next, the correlation between produced saliva and pre-RT SUV was
investigated. In figure 4.7, the relationship between stimulated salvia mass and
pre-RT SUV is shown. Moderate positive correlation between the two metrics,
Pearson correlation = 0.41, was not significant (P>0.05). For the unstimulated
saliva mass produced, stronger negative correlations were observed, Pearson
correlation = -0.57, that were insignificant (P>0.05).

Finally, the relationship

between the subjective XQL summary score and SUV were assessed. This is
shown in figure 4.8. Spearman’s rho showed moderate negative correlation
between the subjective metric and pre-RT SUV, ρ = -0.46, P>0.05.
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Figure 4.6 Baseline parotid SUV distributions

The histogram distribution of parotid SUV values for the “normal” (blue) and
“abnormal” (green) baseline salivary function patients.
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Figure 4.7 Stimulated saliva mass versus SUV

The baseline stimulated saliva mass [g] is plotted as a function of baseline
parotid SUV. Pearson correlation = 0.41, P>0.05.
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Figure 4.8 Baseline XQL score versus parotid SUV

The pre-treatment XQL summary scores did not show a strong correlation to
baseline parotid SUV.

89

Post-RT Salivary Output

Measurements of post-RT saliva production were utilized to establish
salivary toxicity. The average time to first follow-up saliva measurement was 52
days after the completion of RT (range 42 – 62 days).

Although fourteen

patients were analyzed for baseline correlations of saliva mass and SUV, only
eight were employed for the post-RT analysis. The data set was restricted for
several reasons. First, two patients failed to have first follow-up saliva collected.
Second, patients previously identified as having abnormal baseline salivary
function were not included in the analysis, n = 4.

In this manner, potential

confounding factors associated with the deviant salivary function were
eliminated.

The average unstimulated saliva mass produced after RT was 1.16 ±
1.52 g with a range of 0.47 – 4.90 g. The average unstimulated saliva mass
produced was reduced by 49% compared to baseline masses. The distribution
of post-RT unstimulated saliva collected at the first follow-up is shown in figure
4.9. For the stimulated condition, produced saliva had an average mass of 2.26
± 2.08 g. The range of simulated mass was 1.00 – 7.20 g. The stimulated
saliva distribution is shown in figure 4.10. The average stimulated saliva mass
produced was reduced by 50% when compared to baseline. The distribution of
fractional stimulated saliva output is shown in figure 4.11.

Based upon the

EORTC/RTOG Late Effects Analytic Scale, patients with grade 4 (n =2), grade 3
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Figure 4.9 Histogram distribution of post-RT unstimulated salivary mass
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Figure 4.10 Histogram distribution of post-RT stimulated salivary mass
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Figure 4.11 Histogram distribution of fractional stimulated saliva mass
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(n = 3), grade 2 (n = 0), grade 1 (n = 2) and grade 0 (n = 1) xerostomia were
identified.

Correlating Post-RT Salivary Output and SUV

After the pre-RT parotid volumes were deformably mapped to the post-RT
PET/CT images, post-RT SUV was collected for the parotid glands and
correlated with post-RT salivary output measures. In figure 4.12, unstimulated
salivary flow versus absolute post-RT SUV of the parotid glands is plotted.
Apart from one easily identifiable patient, all unstimulated salivary output was
less than 1 g for the five minute collection period. Post-RT SUV for the cohort
ranged from 1.0 – 1.5.

Contrast this with the pre-RT unstimulated salivary

output where 2/3 of the patients with unstimulated flow less than 1 g where
classified as having abnormal baseline flow. Interestingly, the patient with the
greatest post-RT unstimulated salivary mass (4.9 g) also had the greatest preRT unstimulated mass (4.0 g). Because the parotid glands do not produce the
majority of the unstimulated salivary output, correlations between SUV and
unstimulated saliva mass were not expected to be strong nor significant. This
expectation was confirmed (Spearman’s ρ = 0.45, P>0.05).
Next, the stimulated salivary output was investigated. In figure 4.13, the
stimulated saliva mass versus absolute post-RT parotid SUV is plotted. As was
observed for the unstimulated saliva, the stimulated saliva mass range (1.0 – 7.2
g) occupied a small range of SUV values (1.0 – 1.5). The stimulated salivary
mass was expected to correlate much closer with parotid SUV. However, as
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Figure 4.12 Unstimulated saliva mass and SUV

The absolute post-RT unstimulated saliva mass did not correlate strongly with
post-RT parotid SUV. Spearman’s ρ = 0.45, P>0.05

95

Figure 4.13 Stimulated saliva mass and SUV

The absolute post-RT stimulated saliva mass did not correlate strongly with
post-RT parotid SUV. Spearman’s ρ = 0.31, P>0.05
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was observed for baseline stimulated salivary mass and absolute pre-RT SUV,
minimal correlation was observed (Spearman’s ρ = 0.31, P>0.05).
Additionally, the correlation between subjective measures of post-RT
salivary toxicity and SUV were assessed.

The relationship between the

subjective metric and SUV is illustrated in figure 4.14.

As expected XQL

summary score was negatively correlated with SUV, although the results were
not significant (P>0.05).

Finally, relative changes in stimulated salivary output and SUV were
investigated. For 7/8 patients in the cohort, stimulated saliva output at the time
of follow-up imaging was reduced. Fractional stimulated saliva output for this
group was 0.41 ± 0.28. Reduction of saliva output paralleled SUV reduction; the
imaging biomarker value was 0.80 ± 0.14.

One patient’s biomarker value

indicated increased SUV from baseline (1.11). This patient had a corresponding
increase in stimulated saliva output with a fractional stimulated saliva value of
1.14. These metrics demonstrated strong and significant positive correlation
(Pearson correlation = 0.93, P<0.01). The relation is illustrated in figure 4.15.
Furthermore, fractional SUV was correlated with xerostomia grade based on the
RTOG/EORTC late effects analytic scale.

Xerostomia grade was negatively

correlated with fractional SUV (Spearman’s ρ = -0.964, P<0.01). This relation is
shown

in

figure

4.16.
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Figure 4.14 Post-RT XQL score and SUV

The post-RT XQL summary score did not correlate strongly with post-RT parotid
SUV. Spearman’s ρ = -0.56, P>0.05
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Figure 4.15 Fractional stimulated saliva mass and SUV

Fractional SUV was found to be positively correlated

(Spearman’s ρ = 0.93,

P<0.01) with fractional stimulated salivary mass.
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Figure 4.16 Fractional SUV and xerostomia grade
Fractional SUV was found to be negatively correlated (Spearman’s ρ = -0.964,
P<0.01) to xerostomia grade as defined by the RTOG/EORTC late effects
analytic scale.
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Discussion:

Correlations between fractional parotid SUV and stimulated salivary mass
suggest that Parotid SUV can function as an objective imaging biomarker of
salivary function. Patients with parotid glands that had reduced SUV similarly
had reduced stimulated salivary mass following RT. Further, parotid glands that
exhibited increased SUV after RT paralleled increased stimulated salivary mass.
Additionally, parotid gland fractional SUV had a strong negative correlation to
xerostomia grade (P<0.01). These data indicate that parotid SUV measured at
the time of first follow-up after RT (approximately 8 – 9 weeks) may be a good
surrogate for salivary toxicity.

As discussed in chapter 2, the parotid glands are composed of many
spherical clusters of serous cells, known as the acini.

The acinar cells are

responsible for the production of saliva in the parotid glands. In

studies

of

animal parotids, the glandular composition was altered greatly following
irradiation. In one study of the rat parotid, the acinar cells comprised roughly
80% of the glandular volume prior to irradiation. Following the delivery of 30 Gy,
the relative volume occupied by the acini was reduced to 20%. Reduction in the
quantity of acinar cells, responsible for producing the watery secretions,
corresponded to a 90% reduction in the saliva produced [71]. In humans, the
loss of acinar cells at 10 – 12 weeks after the completion of RT has been shown
to be the primary histopathological finding. For the current cohort, first follow-up
salivary measurements were made seven weeks post-RT. While the salivary
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mass measurement was earlier than the 10 – 12 week time frame cited above, a
plausible explanation for the 59% reduction in stimulated salivary flow in 7/8
patients may be the reduction in the number of acinar cells. Furthermore, the
acute phase of parotid damage characterized by the reduction in salivary flow
and lack of alteration in glandular composition in the rat parotid was found to
only last 0 – 10 days after irradiation.

In vivo and in vitro studies have demonstrated that uptake of FDG in
tumors is directly related to the number of viable cells [99, 100]. Specifically, the
numbers of cells expressing the GLUT-1 transporter correlate best with FDG
uptake.

GLUT-1 is a protein that facilitates transport of glucose across the

cellular membrane. Expression of this protein is ubiquitous in human tissue and
is responsible for basal glucose uptake. As the parotid glands are composed
primarily of the serous acinar cells, which express GLUT-1, FDG uptake should
be proportional to the number acinar cells.

By consequence, parotid FDG

uptake may be proportional to saliva production.

Although differences between parotid gland pre-RT SUV for patients
deemed to have abnormal and normal baseline flow were statistically significant,
this determination was arbitrary. Consider the patient classified as abnormal
based upon baseline stimulated salivary mass. This patient produced a salivary
mass of 2.2 g. This was based upon the calculated mass cutoff for a five minute
saliva collection period.

Based upon the low stimulated salivary mass, one

might expect a correspondingly low parotid SUV. It was found that this patient
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had the second lowest pre-RT SUV (1.0). On the other hand, the patient who
produced the greatest baseline stimulated salivary mass (7.8 g) did not have the
greatest baseline parotid SUV (1.6). More telling were the weak correlations
between SUV and stimulated salivary mass. So while SUV may be related to
the quantity of saliva produced, the lack of correlation between pre-RT SUV and
stimulated salivary mass suggests that other cofounding factors are most likely
present. On possible factor is the imperfect correlation between SUV and FDGuptake. Previous reports have shown correlation coefficients as low as 0.84
[99].

Other investigators have found absolute saliva mass is often not the
variable that correlates closest with xerostomia [115].

Rather, it has been

suggested than relative change in an individual’s saliva production is more
important. This logic seems reasonable in light of the wide range of baseline
salivary masses that patients feel constitute normal salivary function (2.55 – 9.46
g). This was confirmed for the current cohort where the strongest correlations
were found between relative changes in stimulated salivary flow and SUV
(Pearson correlation = 0.93, P<0.01). Finally, xerostomia grade was shown to
be negatively correlated with fractional SUV (Spearman’s ρ = -0.964, P<0.01).
This suggests that as patients have SUV values closer to baseline values,
salivary toxicity should be reduced.

This study is limited in several respects. First, the imaging biomarker was
validated against measurements of salivary flow, a metric that is known to have

103

large variability. However, little else exists in the way of objective measures of
salivary toxicity. Second, the study was limited to a small number of patients.
The protocol to establish a database of salivary toxicity from RT at The
University of Texas MD Anderson Cancer Center is one of the first at this
institution. With an accrual goal of 500 patients, the potential to fully investigate
the association between SUV and saliva production is great. Finally, salivary
output was measured as whole mouth salivary mass and not collected from
individual glands. As detailed earlier, saliva results from the contributions of
three major glands in addition to multiple minor glands [60]. Although fractional
SUV correlated well with whole mouth stimulated salivary flow, saliva produced
from other glands was possibly contaminating this measurement. However, this
contamination was expected to be minimal. This is because the submandibular
and sublingual glands receive large enough doses that saliva production after
RT is effectively non-existent [42].
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Conclusions:

In conclusion, pilot data suggest that parotid gland SUV would be well
suited as an imaging biomarker for salivary toxicity. Relative change in parotid
gland SUV correlated significantly with relative change in stimulated whole
mouth salivary flow (P<0.01) and toxicity grade as defined by the RTOG/EORTC
late effects analytic scale (P<0.01). The ability to assess parotid function using
incidentally collected parotid uptake of FDG has great potential to decrease the
reliance on poor measures of salivary toxicity like saliva collection and rarely
used modalities like salivary gland scintigraphy. The results of specific aim 2a
supported the hypothesis.
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Chapter 5

Specific Aim 2b

To quantify and model the dose-metabolic response of the parotid glands in
patients treated with IMRT for head and neck cancer using 18F-FDG PET/CT

Working Hypothesis: Predicted post-RT parotid SUV will correlate with
whole mouth stimulated salivary flow (P<0.05).

Purpose

In the preceding study, Specific Aim 2a, the goal was to evaluate the
potential use of SUV as an objective imaging biomarker of parotid function. In
the small pilot cohort, it was observed that changes in SUV between baseline
and follow-up correlated significantly with changes in stimulated salivary output.
The application of novel imaging biomarkers holds great promise. However, no
matter how well the biomarker may describe the physiologic process in question
it is ultimately limited to describing the current functional status. In the case of
Specific Aim 2a, the dose has been delivered and the parotid glands have been
injured. Simply quantifying the damage can do little to alleviate the salivary
toxicity.
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The purpose of Specific Aim 2b, was to predict parotid post-RT SUV prior
to the delivery of treatment. To accomplish this task, a phenomenological model
of the dose-metabolic response relationship was created using only pre-RT
metrics. The ability to estimate patient specific toxicity holds great promise for
evaluation and refinement of radiation treatment plans.

Methods and Materials:

Patient Cohort

In order to construct a population based model of dose-SUV response,
the patient cohort from Specific Aim 1 was exploited. As described earlier, these
patients received pre- and post-RT PET/CT studies in order to assess and
predict response to radiotherapy for head and neck cancers. The protocol did
not specify the collection of salivary flow measurements, subjective salivary
assessment through xerostomia quality of life questionnaires, or physician
assessment of salivary toxicity. However, as elucidated earlier, the incidental
collection of parotid FDG-uptake can have many tangential uses. Following this
rationale, parotid SUV from patients enrolled in this protocol were utilized to
model the dose-SUV response. Details of the cohort are provided in chapter 3.

To validate the dose-SUV response model, the patient cohort from
Specific Aim 2a was employed. Patients enrolled in this IRB approved protocol
had objective and subjective assessments of salivary function collected, as well
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as, PET/CT imaging studies. Details of the validation cohort are provided in
chapter 4.

Phenomenological Dose-Metabolic Response Model

The relative change in parotid FDG-uptake, expressed as fractional SUV,
at 8 – 9 weeks after the completion of RT was modeled phenomenologically
using pre-RT metrics. As shown previously, for the validation cohort, fractional
SUV had strong and significant correlations to xerostomia grade and fractional
stimulated saliva output. Modeling the continuous variable, fractional SUV, may
allow a richer and more thorough evaluation of salivary toxicity than previous
NTCP techniques that rely upon binary endpoints [116].

Two approaches were employed to model the dose-metabolic response.
First, a mean dose-SUV model was assessed. Second, a voxel-based doseSUV model was constructed. In both scenarios, fractional SUV was modeled as
a function of a single parameter incorporating both planned physical dose and
pre-RT SUV.
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Metabolic Dose

To assess and model the functional dependence of fractional SUV, we
introduced a figure of merit called metabolic dose. The metabolic dose was
defined as,

D Met = Pre - RT SUV [Kg/L] * Physical Dose [cGy]

where physical dose is the clinically planned dose distribution. The metabolic
dose term weights the planned physical dose by the baseline SUV.

In this

manner, voxels with greater planned dose or initial metabolic function are
expected to have greater reductions in baseline SUV than those voxels with
lower planned dose or lower initial metabolic function. Assuming the parotid’s
density is equal to water, the units are in cGy.

The metabolic dose concept is illustrated in figure 5.1. In figure 5.1a, the
relation of the parotid glands and the planned dose distribution is shown. From
the image, it is clear that the most medial portions of the parotid glands will
experience the highest doses. The most medial portions of the parotid glands
are also observed to be the most metabolically active as evident in figure 5.1b.
Consequently, the numeric value of the metabolic dose in this region will be the
highest. As expected, the reduction of SUV in these regions was greatest as
exemplified in figure 5.1d.
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a

b

c

d
Figure 5.1 Metabolic Dose

Approved dose distribution with the parotids illustrated in purple. Skyblue
denotes 45 Gy; green denotes 30 Gy; yellow denotes 26 Gy; and blue, 20 Gy.
(b) Snapshot of baseline parotid SUV. The upper scale represents absolute preRT SUV. (c) Metabolic dose distribution for the parotid glands. (d) Biomarker
distribution for the parotid glands after RT. In the upper scale, SUV is presented
as a fraction of the baseline SUV. Of note is the correspondence between areas
of highest DMet and lowest biomarker
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Volume Delineation
As mentioned above, the parotid metabolic response model was
constructed using the patient cohort from specific aim 1. The parotids for this
cohort were contoured on planning CT images by the treating physician. For the
mean dose-SUV model, the parotid contours were mapped to pre- and post-RT
PET/CT images using the contour mapping workflow specified in specific aim 1.

In the case of the voxel-based model, the parotid contours created on the
planning CT images were once again exploited. However, this model required
one-to-one correspondence between pre- and post-RT SUV as well as dose at
the voxel level. To facilitate this, the enhanced demons algorithm was utilized,
but rather than mapping contours the image sets were deformed. Briefly, the
deformable transformations that resulted from CT-to-CT alignment were applied
to the corresponding PET images.

As a result, the pre- and post-RT PET

images were aligned to the planning CT image. The detailed methodology to
perform this within the CAT workspace is discussed in the next section.

Co-registration of Planned Dose and SUV

The following methodology details the steps required to align PET/CT
images to a reference image set within the CAT image registration workspace.
While not a fusion image viewer, the CAT workspace can be utilized to collect
SUV (Body weight, lean body mass, or body surface area normalization) or
uptake for a volume of interest.
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All serial PET/CT studies were identified in Stentor and uploaded to
Evercore for retrieval as described earlier.

Prior to importing original patient

treatment plans into the CAT workspace, it was necessary to contour the second
cervical vertebrae for image alignment purposes. Contouring was performed
using Philip’s Pinnacle3 treatment planning software, version 7.6c. After opening
the CAT workspace, the original patient treatment plans were imported as
detailed earlier.

The images were then preprocessed. All serial PET/CT studies were first
checked for concordance of slice spacing, thickness, and pixel size. In the event
that one of these imaging parameters did not match, the Image Guided
Radiation Therapy (IGRT) Utilities software package created by our group was
utilized to re-sample the images appropriately. Next, the planning CT imaging
parameters were inspected for concordance with the PET/CT parameters.
Again, if the parameters differed, the image was re-sampled appropriately. By
matching the imaging parameters of each data set we can achieve voxel-byvoxel correspondence for the planning CT and serial PET/CT studies.

The next steps resemble those described in chapter 3 for the contour
deformation methodology.

First, the bony alignment algorithm discussed in

chapter 3 was utilized to align the C2 vertebrae of the reference and daily image
sets. To deform the PET/CT study of interest, the advanced options were used
from the deformation dialog box and batch registration was selected.

Most

importantly, the direction of deformation was specified as Daily -> Reference.
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The DICOM PET images corresponding to the current PETCT study were then
selected. The deformation field mapping the Daily CT to the Reference CT was
applied to each voxel in the PET image, producing a PET image aligned to the
planning CT.

Before dose, pre- and post-RT SUV can be extracted from each contour
the dose from the approved treatment plan must be collected.

Using the

IGRTDumpDose script in the Pinnacle treatment planning system extracted the
required data. Finally, using the advanced options menu, the “Dump PET &
Dose” function was utilized to extract data for every voxel within the contours
contained in the alignment set. The data were output to a text file containing
each voxel location along with dose, pre- and post-RT SUV.

Validation of the Models

After a mathematical form of the dose-metabolic response relationship
was selected, the model was validated using the patient cohort from specific aim
2a.

Initial validation consisted of evaluation of the R2 statistic.

However,

graphical techniques are often the most telling validation of a models
performance. For both the mean and voxel-based dose-SUV response models,
plots of predicted versus observed fractional SUV were constructed.

For a

perfectly performing model, data points on these plots should lie along the line y
= x. Therefore, a well performing model should have a strong linear correlation
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between the predicted and observed values.

Spearman’s correlation was

utilized to assess these correlations and statistically significant results were
defined as having P < 0.05. Relative errors were computed as, (Predicted –
Observed)/Observed *100.

Results:

Fractional SUV and Metabolic Dose

For the mean model, the mean planned dose and pre-RT SUV of the
parotid glands was used.

In figure 5.2, the fractional SUV is plotted as a

function of these two variables.

The average dose delivered to the parotid

glands for the population was 25.4 ± 6.0 Gy. Mean dose to the parotid glands
ranged from 14.4 – 42.8 Gy. The clustering of the mean parotid doses is an
artifact of the planning goal to keep the mean dose less than 26 Gy.

The

fractional SUV observed for the population had an average value of 0.96 ± 0.24.
The fractional SUV range stretched from a minimum value of (0.62) to a
maximum of (1.85). Overall, these data indicated that FDG-uptake was reduced
following delivery of treatment. However, a simple relationship between dose
and fractional SUV did not seem to be present.

The relationship between fractional SUV and the metabolic dose figure of
merit is shown in figure 5.3 for the population. The overall shape of the curve
suggests that fractional SUV has a consistent relationship to the figure of merit
and matches well with the expected dependence.

As stated above, larger
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metabolic dose values were expected to have correspondingly greater
reductions in SUV.

This would translate into smaller fractional SUV values.

Examining the extremes of the plot, a DMet value for one patient of interest was
calculated to be (8667) with a fractional SUV of (0.73). Whereas an example
patient from the lower extreme with a DMet value of (2901) had a fractional SUV
value of (0.90).

The raw data from figure 5.3 were binned for the purpose of modeling.
Five bins were utilized to capture the overall shape of the curve. The width of
each DMet bin was 2600. In figure 5.4, the mean value of each bin with one
standard deviation is displayed.
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Figure 5.2 Fractional SUV dose response

Fractional SUV is plotted as a function of whole organ planned mean dose.
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Figure 5.3 Fractional SUV and DMet
Fractional SUV is plotted as a function of the metabolic dose figure of merit.
DMet is shown deconstructed in this plot.
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Figure 5.4 Fractional SUV and DMet
The average fractional SUV is plotted against the mean metabolic dose for each
bin of width 2600. The error bars represent one standard deviation.

118

Validation of the Mean Model

For the mean dose-SUV model, the fractional SUV was modeled over a
range of DMetabolic values extending from a minimum of 2235 to a maximum of
7115. A power law with a constant offset was selected to model the data over
the range of values found in this population. The functional form of this model is

f ( x) = a * x b + c
where a, b, and c represent the coefficients.

In the above equation, x

represents the metabolic dose figure of merit. The results of the non-linear least
squares fit are shown in figure 5.5. The constant a value was calculated to be
3.6x105 with 95% confidence bounds of -2.8x106, 3.6x106. The constant b value
was found to have a value of -1.7 with 95% confidence bounds of (-2.88, -0.52).
Finally, the offset constant, c, had a value of 0.65 with 95% confidence bounds
of (0.42, 0.87). The adjusted R2 statistic for the fit was found to be 0.996. The
sum of squares due to error (SSE) was found to be 0.0004.

Next, the patient cohort from specific aim 2b was used to further validate
the phenomenological model.

In figure 5.6, a scatter plot of the observed

fractional SUV for this cohort versus the fractional SUV predicted from the mean
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dose-SUV model is shown. The dotted line represents a perfectly performing
model. The mean relative error between the predicted and observed fractional
SUV was 13%. The maximum and minimum relative errors found were 76% and
-13%, respectively. The most accurately predicted fractional SUV had a relative
error of 0.07%.

For the patient with the largest relative error the observed

fractional SUV was (0.47), but the predicted value was (0.83). However, this
patient was classified as having “abnormal” baseline salivary function. Finally,
the predicted and observed values were found to have a strong and significant
correlation, Spearman’s ρ=0.71, P<0.01. The combination of fit statistics and
graphical analysis indicate the phenomenological model performs well.

Lastly, the correlation between the predicted fractional SUV and the
observed fractional stimulated salivary output was assessed. In figure 5.7, the
fractional stimulated salivary mass is shown to be significantly correlated with
predicted fractional SUV, Spearman’s rho = 0.79, P<0.05.

As observed in

specific aim 2a, only one patient had SUV that increased beyond baseline and
this corresponded to an increase in stimulated salivary mass. However, the
mean model predicts that two patients would have SUV increases from baseline.
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Figure 5.5 Fitting results for the mean model

Mean metabolic dose and fraction SUV data are plotted with the resulting
weighed fit for a constant offset power law.
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Figure 5.6 Mean model validation

The observed fractional SUV values are plotted against the fractional SUV
values predicted from the mean model (Spearman’s ρ = 0.71, P<0.01).
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Figure 5.7 Predicted SUV and observed saliva changes

The observed fractional stimulated saliva mass was plotted as a function of the
predicted fractional SUV (Spearman’s ρ = 0.79, P<0.05).
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Voxel-based Fractional SUV and Metabolic Dose

The second technique used to construct the phenomenological model
was voxel-based. After co-registration of pre- and post-RT SUV with planned
dose, the voxel data were binned. The bin width was set at 2000, but expanded
for the highest metabolic dose values to increase the number of voxels in the
most starved bins. In figure 5.8, the relationship between the metabolic dose
figure of merit and fractional SUV as determined on a voxel-by-voxel basis may
be examined. The error bars represent one standard deviation.

Once again a consistent relationship between the two variables was
observed. Furthermore, the shape of the distributions also conformed to the
initial expectations of an inverse relationship between the fractional SUV and the
metabolic dose figure of merit. Of particular interest is the much wider range of
metabolic dose values observed.

For the mean model, the metabolic dose

metric range was up to 6.5x103, whereas the range for the voxel model was an
order of magnitude larger, up to approximately 7.8x104. As alluded to earlier,
the narrow range of mean doses delivered to the parotid glands is the primary
reason for the constricted range. However, on a voxel-by-voxel basis the dose
range was much larger, 67 Gy versus 28 Gy found for mean planned doses to
the whole parotid glands. Because of this, the voxel model is able to account for
dose heterogeneities within the parotid glands.
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Figure 5.8 Voxel-based dose-SUV response

The fractional SUV-metabolic dose relationship for the entire cohort was
compiled for the entire cohort.
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Validation of the Voxel Model

The A log transform of the fractional SUV and metabolic dose was utilized
to aide in the fitting. A modified logistic function was utilized to model fractional
SUV at the voxel level as a function of metabolic dose. The functional form has
been modified to prevent fractional SUV values of zero. Additionally, a boundary
condition was imposed on the voxel data. At zero metabolic dose the fractional
SUV is assumed to be one. This means that if the patient were to receive no
dose the SUV value should remain at baseline values. The functional form of
this model is

f ( x) =

a
  x
1+ b * 
 c


where, a-e represent the coefficients.

d






+e

In the above equation, x represents the

metabolic dose figure of merit. The results of the linear least squares fit are
shown in figure 5.9. The constant a value was calculated to be 0.4669 with 95%
confidence bounds of (0.4434, 0.4905). The constant b value was found to have
a value of 7.599 with 95% confidence bounds of (5.287, 9.912). The constant c
that scales the metabolic dose value was found to have a value of 2.25 x 104
with 95% confidence bounds of (2.1 x 104, 2.8 x 104).

The power value,

126

constant d, was found to have a value of 3.943 with 95% confidence bounds of
(3.181, 4.706). Finally, the offset constant, e, had a value of 0.5324 with 95%
confidence bounds of (0.513, 0.5517). The adjusted R2 statistic for the fit was
found to be 0.9987. The sum of squares due to error (SSE) was found to be
0.0007.

Next, the patient cohort from specific aim 2b was again used to validate
phenomenological model. In figure 5.10, a scatter plot of the observed fractional
SUV for this cohort versus the fractional SUV predicted from the voxel-based
dose-SUV model is shown. The dotted line represents a perfectly performing
model. The mean relative error between the predicted and observed fractional
SUV was 9.6%. The maximum and minimum relative errors found were 65%
and -22%, respectively. The most accurately predicted fractional SUV had a
relative error of approximately 0.2%.

The patient with “abnormal” baseline

salivary function also plagued the voxel-based model.

For this patient the

observed fractional SUV was (0.47), but the predicted value was (0.65). The
voxel-based model was able to improve the predicted fractional SUV for this
patient, but still failed to fully describe the extent of SUV reduction. There were
two addition patients where fractional SUV was noticeably overestimated, 46%
and 25%. The fractional SUV was underestimated markedly for one patient.
The observed fractional SUV in this case was (1.23), but the predicted value
was only (0.96). This represented a roughly 22% underestimation. This patient
also had “abnormal” baseline salivary function.

Finally, the predicted and

observed values were found to have a strong and significant correlation,
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Spearman’s ρ=0.94, P<0.01. The combination of the adjusted R2 and graphical
analysis indicate the voxel-based phenomenological model performed at least
as well as the mean dose-SUV model and in many cases better. Overall, the
relative error was reduced from 13% to 9%.

Lastly, the correlation between the predicted fractional SUV and the
observed fractional stimulated salivary output was assessed. In figure 5.11, the
fractional stimulated salivary mass is shown to have a strong and significant
correlation with our figure of merit, Spearman’s rho = 0.85, P<0.01.
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Figure 5.9 Fitting results for the voxel model

Mean metabolic dose and fraction SUV data are plotted with the resulting
modified logistic model fit.
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Figure 5.10 Voxel model validation

The observed fractional SUV values are plotted against the fractional SUV
values predicted from the mean model (Spearman’s ρ = 0.94, P<0.01).
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Figure 5.11 Predicted SUV and observed saliva changes

The observed fractional stimulated saliva mass was plotted as a function of the
predicted fractional SUV (Spearman’s ρ = 0.85, P<0.01).
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Discussion

Predicting normal tissue toxicity has long been a goal to improve patient
outcomes [117]. Fully understanding the response of normal tissues is vitally
important in determining tolerance doses. Dose response modeling utilizing in
vivo biomarkers offers the possibility for patient specific estimations of toxicity
based upon biologic function. Additionally, in comparison to other image-based
dose-response studies, PET/CT offers a 3D technique that many clinicians have
routine experience with [4, 45]. However, exploiting

18

F-FDG PET/CT for dose-

response modeling is still in an embryonic stage [106, 107].

The first model developed as part of this thesis work was a mean parotid
dose and SUV model.

Although the range of mean doses delivered to the

parotid glands only spanned 28.4 Gy, mean dose to the parotid glands has been
shown to be one the strongest predictors of salivary toxicity [39]. However, as
shown in figure 5.2, a simple relationship between Dose and relative SUV
change in the parotid glands was not evident. We hypothesized that in addition
to the mean dose delivered to the parotid glands, the baseline function of the
glands should also be relevant. A figure of merit called the metabolic dose was
introduced to capture this interplay between the spatial dose distribution and
glucose metabolism. Because SUV is known to be proportional to the number of
viable cells, dose delivered to more metabolically active regions were weighed
more heavily with this metric and expected to experience greater reductions in
SUV after treatment. Although the selection of the metabolic dose metric was
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serendipitous, motivation for its selection can be found through multivariate
fractional polynomial regression analysis [118, 119]. This type of regression
analysis is useful when the covariates in the model may be non-linear. Utilizing
the statistical package R, the influence of dose, pre-RT SUV, and the metabolic
dose metric on regression models of fractional SUV was assessed using the
voxel-based data. While none of the three covariates listed were eliminated
from the final model, the coefficients were illuminating as to the best metric for
SUV response modeling.

For dose, the coefficient was -6.7 x 10-8 and the

coefficient for pre-RT SUV was 8.5 x 10-2. However, when the product of dose
and pre-RT SUV, metabolic dose, was considered the coefficient was -2.5. The
coefficient for the metabolic dose metric was at least two orders of magnitude
larger than the separated covariates. This indicates that metabolic dose is the
dominate covariate and supports the use of this figure of merit for modeling the
SUV response relationship. A plot of metabolic dose and parotid SUV relative
change displayed a consistent relationship that conformed to expectations. The
mean model was fit with a constant offset power law. The fit statistics indicated
a good fit, but because the metabolic dose metric and fractional SUV are
correlated this was expected.

One of the potential drawbacks of the phenomenological model is that it
was only applicable over the range of observed data. Beyond these limits the
model is ill behaved.

For instance, as the metabolic dose increases, the

fractional SUV will asymptotically approaches the constant offset, which for this
cohort was 0.65. However, suggesting that parotid SUV relative change has a
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minimum of 65% of baseline may be unrealistic.

Interesting and perhaps

unsurprisingly, given the fractional SUV dependence observed, only three
parotid glands broached this barrier in the model cohort. For the test cohort, two
patients were below the minimum value of 65%, one of which had abnormal
baseline salivary function.

At the other extreme, as metabolic dose values

approach zero the relative change goes to infinity.

This seems to be

physiologically unlikely. Increases in glucose metabolism are possible and were
observed, but setting a ceiling value for increase is unclear. In one study by
Schwartz-Arad et al., the effects of compensatory hyperplasia following partial
submanibulectomy

in

rats

found

increased

salivary

function

and

an

approximately 154% increase in the number of acinar cells the remaining
submandibular gland [120].

Graphical validation of the mean model was favorable. Scatter plots of
the predicted and observed fractional SUV for the mean model demonstrated
highly positive correlation (ρ = 0.71, P<0.01). Furthermore, because the ultimate
goal is to predict the fractional SUV that would result from treatment prior to its
actual delivery, observed changes in stimulated salivary mass were plotted
against predicted changes in SUV. Although highly correlated (Spearman’s ρ =
0.79, P<0.05), when compared to figure 4.15 in chapter 4, it is apparent that the
relation between fractional SUV, which serves as the imaging biomarker, and
relative change in stimulated salivary mass was altered.

Specifically, when

fractional SUV was evaluated as a biomarker only one individual had an
increase in SUV and this corresponded to an increase in stimulated salivary
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mass. For the predicted values, two patients were predicted to have increases
in SUV and it would be expected that both might have increased salivary output.
However, this was not true for one of these patients and the actual stimulated
salivary mass decreased by almost 20%. Overall the mean dose-SUV response
model represented an easily implementable method that, with further validation,
may allow for individualized assessment of the salivary toxicity resulting from a
treatment plan design.

The second method used to construct the dose-SUV response model was
based upon voxel-by-voxel correspondence of dose and SUV. The benefit of
this model is the ability to account for subtle differences in the spatial distribution
of planned dose.

Figure 5.12 illustrates this with two similar dose volume

histograms that led to very different functional outcomes. The range of doses
available at the voxel level was much larger than those available when whole
organ mean dose was used (67 Gy vs. 28 Gy). Because of this, a richer picture
of the metabolic response was possible.

This was reflected in the reduced

relative error for the voxel-based model (9% vs. 13%). An examination of the
observed vs. predicted fractional SUV plot showed that the model performed
quite well (Spearman’s ρ = 0.94, P<0.01).
The voxel-based relationship between the metabolic dose figure and
fractional SUV suggested a sigmoidal dependence. The general trend of this
data matches with that found in scintigraphic studies of parotid gland excretion
as measured by reductions in tracer uptake. The voxel-based model differed
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from the mean model in that whole organ function was reconstructed from subglandular response. By predicating sub-glandular response, the voxel-model
was able to account for variations in the spatial distribution of dose. However,
this also meant that the voxel-based model was more susceptible to the
accuracy of the dose calculation engine.

One recent study compared the

Pinnacle3 version 7.6c superposition/convolution algorithm with Monte Carlo
(EGS4) calculations for head and neck IMRT patients.

Mean doses to the

ipsilateral and contralateral parotid only differed by -0.5% and -0.04%,
respectively [121]. For the mean dose model, errors in the calculated dose were
minor. However, calculated doses from the surface down to 2 mm depth were
shown to have relative errors that exceeded 5%. The most superficial border of
parotid glands was found at approximately 2 mm depth.

Even with these

potential differences between the delivered and calculated dose, whole organ
fractional SUV constructed from sub-glandular response agreed well with
observed values of SUV.

Additionally, the ability of the voxel-based model to account for potential
hyperplasia may be limited. As seen in figure 5.8, the voxel data failed to show
evidence of SUV increases from baseline for low metabolic dose values.
However, parotid mean SUV was observed to increase from baseline. If the
voxel-based model is utilized to reconstruct parotid mean SUV it will fail to
account for observed increases.
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Figure 5.12 Parotid DVH comparisons

For a high (square) and low (triangle) oral complication patient, the cumulative
DVH displays surprisingly subtle differences. Both patients had a whole organ
planned mean dose less than 26 Gy.
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Consider a patient that had an observed increase in SUV of 23%. The
mean model predicted an increase of 10% while whole organ SUV reconstructed
from the voxel-based model predicted an SUV decrease of 4%.

For the mean

dose and SUV data, increases in SUV from baseline were observed.

Conclusions

In conclusion, the dose-SUV response relationship in the human parotid
glands was quantified and modeled. Utilizing only baseline metabolic function
and the planned dose distribution, predicting parotid SUV change or salivary
toxicity, based upon specific aim 2, became possible. Two techniques were
used to create the phenomenological models:

1) based upon whole organ

planned mean dose and pre-RT SUV and 2) based upon dose and SUV at the
voxel level. Mean and voxel-based models performed well at predicting SUV
changes in a validation cohort with relative errors of 13% and 9%, respectively.
Predicted SUV changes and observed stimulated saliva mass changes
correlated strongly for both models although some shifting of the relationship
observed in specific aim 2a was observed. The results of this aim supported the
hypothesis.
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Chapter 6

Summary and Conclusions

Central Hypothesis:

We hypothesize that more accurate image registration will lead to
improved quantitation of tissue response to radiotherapy with

18

F-FDG PET/CT

imaging.

Conclusions

The central hypothesis of this work was an overarching statement that
connected the myriad applications of

18

F-FDG PET/CT investigated in this work.

As described in the pages above, quantitative treatment response monitoring
with

18

F-FDG PET/CT holds great promise.

Colloquially, treatment response

monitoring has referred to analysis of only neoplastic tissue. However, such a
narrow application of a paradigm changing technology will limit novel ways to
improve patient management. As such, this work was designed to improve upon
the existing uses of this modality and expand its use to new and interesting
vistas.

In the first specific aim, the purpose was to apply deformable image
registration techniques to a study designed to assess and predict response to
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RT using PET/CT. Total tumor volumes, defined on CT and PET images, and
the most metabolically active volumes were investigated to find the most
accurate method to judge response. Secondly, two methods of aligning these
volumes to serial PET/CT studies were tested.

The first relied upon a

deformable image registration algorithm, while the second employed a more
conventional bony alignment technique.

The deformably mapped SUVPeak

volume was the best metric for predicting response to RT. The PPV (63%) of
this metric was greater than post-RT contrast enhanced CT (50%) and all other
PET metrics (40%, 21%, and 57%). When compared to bony alignment of the
SUVPeak volume, deformable image registration led to significantly improved
prediction of response to RT. Specific aim 1 supported the working hypothesis
that voxel-by-voxel mapping of primary volumes to serial F-FDG PET/CT images
would improve region based tumor response analysis.

In the second specific aim, the goal was to evaluate the use of a novel
imaging biomarker for salivary function following RT. To our knowledge, this
was the first time the relationship between salivary output and salivary gland
uptake of 18F-FDG has been investigated. Relative change in parotid gland SUV
was found to have strong and significant correlations to relative change in
stimulated salivary mass (Pearson correlation = 0.93, P<0.01).

Utilizing the

RTOG/EORTC Late Effects analytic scale, patients were stratified into
xerostomia grade. Although limited by patient number, individuals with parotid
SUV closer to baseline values were found to have lower grade xerostomia at the
time of first follow-up (Spearman’s ρ = -0.96, P<0.01). Mapping pre-RT parotid
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volumes across serial imaging studies yielded a novel method to assess salivary
toxicity due to RT. Specific aim 2a supported the hypothesis that parotid gland
SUV would function as an objective imaging biomarker of salivary toxicity,
correlating with stimulated salivary flow (P<0.05).

In the third specific aim, the goal was to construct a model of the doseSUV response relationship in the parotid glands to allow for pre-treatment
prediction of post-treatment parotid SUV values. Utilizing a figure of merit that
captured both the planned dose and pre-RT SUV of the parotid glands, a
phenomenological model of the relative change in SUV due to RT was
formulated. Two models were built, one based upon planned mean dose to the
parotids and mean SUV and a second model based upon dose and SUV at the
voxel level in the parotid glands. Predicted and observed relative change in
SUV correlated well for both the mean (Spearman’s ρ = 0.71, P<0.01) and
voxel-based (Spearman’s ρ = 0.94, P<0.01) models.

Subsequently, the

predicted relative change in parotid SUV, which was shown to function well as
an imaging biomarker for salivary toxicity in specific aim 2a, was shown to
correlate closely with the observed relative change in stimulated salivary mass
at the time of first follow-up. Co-registration of pre- and post-RT PET/CT images
with planned dose distributions, achieved through the use of deformable image
registration tools, made possible this novel dose-SUV response model. To our
knowledge, this is the first time the feasibility of such a model for the human
parotid glands has been demonstrated.

Specific aim 2b supported the
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hypothesis that predicted parotid post-RT SUV would correlate with whole mouth
stimulated salivary flow (P<0.05).

The central hypothesis of this work was that more accurate image
registration would lead to improved quantitation of tissue response to RT with
18F-FDG PET/CT.

In each aim deformable image registration facilitated

improved quantitation for tumor as well as normal tissue.

The future of

radiotherapy will most certainly see increased use of 18F-FDG PET/CT imaging
for quantitative treatment response monitoring. The application of deformable
image registration to quantitative treatment response monitoring with 18F-FDG
PET/CT could have a profound impact on patient management. Accurate and
early identification of residual disease may allow for more timely intervention,
while the ability to quantify and predict toxicity of normal OAR might permit for
individualized refinement of radiation treatment plan designs.
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Appendix

Addhdrinfo

The following code will add user specified content to DICOM PET image
headers, copy all unaltered content, and create a new set of images containing
user generated content.

function Addhdrinfo
%The following script will add a DICOM tag or alter a current tag in a
%group of images
%CAUTION!!
alter
%code!

Unitl updated for user input of tag or tag value, MUST

PathName = uigetdir;
d = datestr(now,30);
mkdir(PathName,['Altered Images',d]);
%get the file list in the given directory
structFilesList = dir(PathName);
structFilesList(1:2) = [];
%delete the default system directory name
%Convert struct FilesList to char array
cellFilesList=struct2cell(structFilesList);
cellFilesName=cellFilesList(1,:);
%Delete folder name
TempDirFlag=cellFilesList(4,:);
TempDirFlag=cell2mat(TempDirFlag);
TempDirOrder=find(TempDirFlag);
if ~isempty(TempDirOrder)
cellFilesName(TempDirOrder)=[];
end
charFilesName=char(cellFilesName');
FileName=cellstr(charFilesName);
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%Set the duration of the for loop by the number of patients in the
selected
%directory
ptcnt=size(FileName, 1);
%Read file and alter DICOM tags
for i=1:ptcnt
%Filter to skip files without the .dcm file extension
TempFile=FileName{i};
%Checks the files for the .dcm extension, if not .dcm exits loop
and
%moves to the next file in the list
if length(TempFile)> 4
if ~isequal(TempFile(end-3:end), '.dcm')
continue;
end
else
continue;
end
%Writest the dicom header to a cell array
X =[PathName, '\', FileName{i}];
img=dicomread(X);
metadata = dicominfo (X, 'dictionary','DicomDict_Plan.txt');
%DICOM tag to be added or altered
metadata.PatientSize = 1.65;
%Creates a new DICOM image with altered an altered DICOM tag
dicomwrite(img,[PathName,'\','Altered
Images',d,'\',FileName{i}],...
metadata,'CreateMode','copy');
end

Scanorder

The following script will open a series of images and place them in folders
based upon chronology e.g. CT01, CT02 etc.

%This script will rename image directories either to CT01 or CT02 and
PET01
%or PET02
PathName = uigetdir;
%Get the file list in the given directory
FolderStruct = dir(PathName);
%Delete the default system directory name
FolderStruct(1:2) = [];

144

%Create structure of subdirectories
for i=1:size(FolderStruct,1)
tempsubdir = dir([PathName,'\',FolderStruct(i,1).name]);
tempsubdir(1:2) = [];
if size(tempsubdir,1)> 1
disp([FolderStruct(i,1).name, ' has more than one series']);
continue;
end
structFilesList = dir([PathName,'\',FolderStruct(i,1).name,'\',...
tempsubdir.name]);
%delete the default system directory name
structFilesList(1:2) = [];
%Convert struct FilesList to char array
cellFilesList=struct2cell(structFilesList);
cellFilesName=cellFilesList(1,:);
%Delete folder name
TempDirFlag=cellFilesList(4,:);
TempDirFlag=cell2mat(TempDirFlag);
TempDirOrder=find(TempDirFlag);
if ~isempty(TempDirOrder)
cellFilesName(TempDirOrder)=[];
end
charFilesName=char(cellFilesName');
FileName=cellstr(charFilesName);
img =[PathName,'\',FolderStruct(i,1).name,'\',...
tempsubdir.name, '\', FileName{1}];
info = dicominfo(img, 'dictionary','DicomDict_Plan.txt');
FolderStruct(i,1).creationdate = info.InstanceCreationDate;
end
if (FolderStruct(1,1).name(1:2) == 'CT' & FolderStruct(2,1).name(1:2)
== 'CT')
if (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(2,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\CT01']);
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\CT02']);
if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(4,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET01']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET02']);
else
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET02']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET01']);
end
elseif (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') == ...
datenum(FolderStruct(2,1).creationdate,'yyyymmdd'));
disp('Pre- and post-RT scans have same date.');
continue;
else
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movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\CT02']);
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\CT01']);
if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(4,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET01']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET02']);
else
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET02']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET01']);
end
end
elseif (FolderStruct(1,1).name(1:2) == 'PE' &
FolderStruct(2,1).name(1:2) == 'PE')
if (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(2,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\PET01']);
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\PET02']);
if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(4,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT01']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT02']);
else
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT02']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT01']);
end
elseif (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') == ...
datenum(FolderStruct(2,1).creationdate,'yyyymmdd'));
disp('Pre- and post-RT scans have same date.');
continue;
else
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\PET02']);
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\PET01']);
if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ...
datenum(FolderStruct(4,1).creationdate,'yyyymmdd'));
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT01']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT02']);
else
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT02']);
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT01']);
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end
end
else
disp('Not all PET/CT series present');
end
clear;

Pthdrinfo

The following script will extract user specified content from a series of
DICOM image headers and place all desired data into an excel file.

function Pthdrinfo
%Extract info from DICOM headers
%Specifically for PET images
%See line 74 for list of tags captured
PathName = uigetdir;
%get the file list in the given directory
structFilesList = dir(PathName);
structFilesList(1:2) = [];
%delete the default system directory name
%Convert struct FilesList to char array
cellFilesList=struct2cell(structFilesList);
cellFilesName=cellFilesList(1,:);
%Delete folder name
TempDirFlag=cellFilesList(4,:);
TempDirFlag=cell2mat(TempDirFlag);
TempDirOrder=find(TempDirFlag);
if ~isempty(TempDirOrder)
cellFilesName(TempDirOrder)=[];
end
charFilesName=char(cellFilesName');
FileName=cellstr(charFilesName);

%Set the duration of the for loop by the number of patients in the
selected
%directory
ptcnt=size(FileName, 1);
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%Create data matrix
Ptdata=[];
%Read file and extract DICOM tags
for i=1:ptcnt
%Filter to skip files without the .dcm file extension
TempFile=FileName{i};
%Checks the files for the .dcm extension, if not .dcm exits loop
and
%moves to the next file in the list
if length(TempFile)> 4
if ~isequal(TempFile(end-3:end), '.dcm')
continue;
end
else
continue;
end
%Writest the dicom header to a cell array
img =[PathName, '\', FileName{i}];
info = dicominfo (img, 'dictionary','DicomDict_Plan.txt');
%Determines if the header is from a PET image, ie
Radiopharmecuticals,
%if not, sets those fields as zero
if isfield(info, 'RadiopharmaceuticalInformationSequence') &&
ischar('RadiopharmaceuticalInformationSequence.Item_1.Radiopharmaceutic
alStartTime')&&
ischar('RadiopharmaceuticalInformationSequence.Item_1.RadionuclideTotal
Dose');
Ptx =
[str2num(info.PatientID),str2num(info.StudyDate),info.PatientSize,
info.PatientWeight,info.SliceThickness,...
str2num(info.SoftwareVersion),info.ReconstructionDiameter,info.PixelSpa
cing(1),info.RescaleSlope,...
str2num(info.AcquisitionTime),str2num(info.SeriesTime),...
str2num(info.RadiopharmaceuticalInformationSequence.Item_1.Radiopharmac
euticalStartTime),...
info.RadiopharmaceuticalInformationSequence.Item_1.RadionuclideTotalDos
e,{info.ManufacturerModelName},{info.CorrectedImage}];
else
Ptx =
[str2num(info.PatientID),str2num(info.StudyDate),info.PatientSize,
info.PatientWeight,info.SliceThickness,...
str2num(info.SoftwareVersion),info.ReconstructionDiameter,info.PixelSpa
cing(1),info.RescaleSlope,...
str2num(info.AcquisitionTime),str2num(info.SeriesTime),0,0,0,0];
end
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%Writes tags to a matrix
Ptdata=[Ptdata; Ptx];
end
%Character array that is written to excel file as label for data
hdr = {'MRN','Date', 'Patient Height (m)', 'Patient Weight (kg)',
'Slice Thickness (cm)','Software Version','Recon Diameter (mm)','Pixel
Spacing (mm)',...
'Rescale Slope','Acquisition Time (HHMMSS)','Series Time
(HHMMSS)','RadioPharm Start Time (HHMMSS)','Dose (Bq)','Model
Name','Applied Corrections'};
%Write patient data matrix to excel file
d = datestr(now,30);
xlswrite([PathName,'\','Header Data','_',d,'.xls'],hdr,'Header Data');
xlswrite([PathName,'\','Header Data','_',d,'.xls'],Ptdata,'Header
Data','A2');

PETThreshold
The following script is designed for use with the Pinnacle3 treatment
planning system to create threshold contours on PET images.

// Recalculate stats for max pixel
RoiList.# "Max Pixel".RecomputeStatistics="";
// Autocontour 50% threshold
Store.FloatAt.Fifty = RoiList.# "Max Pixel".MaxDisplay;
Store.At.Fifty.Multiply=0.5;
RoiList.# "50Primary".AutoLower = Store.At.Fifty.Value;
RoiList.# "50Primary".MakeCurrent="";
RoiList .# "50Primary".AutoContourROI = "Current Region Of Interest";
Store.FreeAt.Fifty="";
// Change 50% threshold data set to CT
Store.StringAt.CTdata = RoiList.# "C2".VolumeName;
RoiList.# "50Primary".VolumeName = CTdata;
// Cleanup ROI
RoiList .Current .Clean = "Rescan";
RoiList .Current .CleanAndDelete = "Delete Curves";
//Eliminate all autocontours in head
RoiExpandControl.SourceRoiList.Current.Remove="";
RoiExpandControl.AvoidRoiList.Current.Remove="";
RoiExpandControl.TargetRoi.Remove="";
RoiList.Current="50Primary";
RoiExpandControl .AddSourceRoi = "Add -->";
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RoiList .Current
RoiExpandControl
RoiExpandControl
RoiExpandControl
RoiExpandControl

= "Head";
.AddAvoidRoi = "Add -->";
.Expand = 0;
.TargetRoi = "na";
.DoExpand = "Proceed";

// Remove curves from 50Primaryrimary
RoiList.Current="50Primary";
RoiList.Current.RemoveAllCurves = "";
Test.ExpectAskYesNo = 1;

//Move 50% threshold curves from NA back to 50Primary
RoiExpandControl.SourceRoiList.Current.Remove="";
RoiExpandControl.AvoidRoiList.Current.Remove="";
RoiExpandControl.TargetRoi.Remove="";
RoiList .Current = "na";
RoiExpandControl .AddSourceRoi = "Add -->";
RoiExpandControl .Expand = 1;
RoiExpandControl .TargetRoi = "50Primary";
RoiExpandControl .DoExpand = "Proceed";
// Remove curves from NA
RoiList .Current = "na";
RoiList.Current.RemoveAllCurves = "";
Test.ExpectAskYesNo = 1;

petctfusion

The following script is a command line fusion image viewer designed for
use with CT images and compressed PET images in the *.txtimg format. Of
particular importance is the DualMap.m script for combined colorbars

function [RTstruct RTalphamap AxialImage, CTmax, CTrange,path,file] =
petctfusion(x)
%The following script will create a dual color map PET/CT figure. The
CT
%image set should be a reference and the PET overlay should be an ROI.
The
%input should be the slice number.
%Select the reference image set
[Xpixels, Ypixels, ZsliceNum, AxialImage] = OpenPinnacleImages;
%Select the overlay structure
[RTstruct,path,file] = OverlayImg(Xpixels,Ypixels,ZsliceNum);
%Perform a hard W/L on the reference CT images
[AxialImage,CTmax,CTrange] = SoftTissue(AxialImage);
%Create the aplha map to determine opacity of the overlay image
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RTalphamap=RTalpha(RTstruct);
%Create the figure with a dual color map
DualMap(AxialImage, RTstruct,x,RTalphamap,CTmax,CTrange);

OpenPinnacleImages

The following script was utilized to open binary format images compatible
with the Pinnacle3 treatment planning system.

function [Xpixels, Ypixels, ZsliceNum, AxialImage] =
OpenPinnacleImages(hdr)

if isdir(['G:\Research\Head and Neck\H&N PET_CT deformable
registration\'...
'Data and Analysis\Data\']);
[file path FilterIndex]=uigetfile('*.header','Select image header
file.',...
['G:\Research\Head and Neck\H&N PET_CT deformable
registration\'...
'Data and Analysis\Data\']);
hdr = [path file];
imfile = [file(1:end-6) 'img'];
else
[file path]=uigetfile('*.header','Select image header file.');
hdr = [path file];
imfile = [file(1:end-6) 'img'];
end

%The following function will open Pinnacle CT images
HeaderInfo=textread(hdr, '%s', 'delimiter', '\n');
a=char(39);
HeaderInfo = regexprep(HeaderInfo, '"', a);
%Get Byte order, actual operation
for kk=1:20
eval(HeaderInfo{kk});
end
Xpixels=x_dim;
Ypixels=y_dim;
ZsliceNum=z_dim;
%Read daily pinnalce data
if byte_order == 0
fid=fopen([path imfile], 'r', 'ieee-le');
else
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fid=fopen([path imfile], 'r', 'ieee-be');
end

[TempData, Count]=fread(fid, Xpixels*Ypixels*ZsliceNum, '*int16');
TempData=uint16(TempData);
fclose(fid);
AxialImage=reshape(TempData, [Xpixels, Ypixels, ZsliceNum]);
AxialImage=permute(AxialImage, [2,1, 3]);

OverlayImg

The following code will turn the compressed image files in the *.txtimg
format into false color images that can be fused with grayscale CT images.

function [RTstruct,path,file] = OverlayImg(Xpixels,Ypixels,ZsliceNum)
%This code will turn the *.txtimg files into useable images based upon
%outputs from the OpenPinnacleImages function
if isdir(['C:\Documents and Settings\bacannon\My
Documents\Research\']);
[file path FilterIndex]=uigetfile('*.txtimg','Select text image
file.',...
['C:\Documents and Settings\bacannon\My Documents\Research\']);
img = [path file];
%imfile = [file(1:end-6) 'img'];
else
[file path]=uigetfile('*.txtimg','Select text image file.');
img = [path file];
%imfile = [file(1:end-6) 'img'];
end
fid = fopen(img,'r');
%The following function will open the text image file
Temp = textscan(fid,'%-15.0f%-15.0f%-15.0f%-15.4f%-15.4f%-15.4f%15.4f');
ImgData = [Temp{1},Temp{2},Temp{3},Temp{4},Temp{5},Temp{6},Temp{7}];
clear Temp;
fclose(fid);
%Create the empty matrix that will be the image
RTstruct = zeros (Xpixels, Ypixels, ZsliceNum);
%Determine the indcies for the data in the volumetric data set
IND = sub2ind(size(RTstruct),ImgData(:,2),ImgData(:,1),ImgData(:,3));
%Place value of interest as pixel value
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%Column 1 - 3: x, y, and z location
%Column 4: Fractional uptake
%Column 5: Mean metabolic dose
%Column 6: Mean SUV1
%Column 7: Mean SUV2
%By changing the data one must alter line 55 of DualMap.m
RTstruct(IND) = ImgData(:,6);
clear IND ImgData

SoftTissue

The following script will perform a hard window/level operation to set the
dynamic range of CT images to a soft tissue window.

function [AxialImage,CTmax,CTrange] = SoftTissue(AxialImage)
%This function will rescale the CT data to be in the soft tissue window
%range
CTmax = int16(1200);
CTrange = int16(400);
X = size(AxialImage,1);
Y = size(AxialImage,2);
Z = size(AxialImage,3);
%Rescal the CT image to the soft tissue window
for i=1:(X*Y*Z)
if AxialImage(i) < 800;
AxialImage(i)=800;
elseif AxialImage(i) > 1200;
AxialImage(i)=1200;
else
end
end

RTalpha

The code given below was utilized to create an opacity mask for the
overlay images.

function RTalphamap=RTalpha(RTstruct)
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X = size(RTstruct,1);
Y = size(RTstruct,2);
Z = size(RTstruct,3);
RTalphamap = zeros (X,Y,Z);
for i=1:(X*Y*Z)
if RTstruct(i)==0
RTalphamap(i)= 0;
else
RTalphamap(i)=1;
end
end

DualMap

The following script is the most critical for image overlay in the MATLAB
workspace.

function DualMap(AxialImage, RTstruct,x,RTalphamap,CTmax,CTrange)
%The following script will create a dual color map image with fused
%AxialImage and overlay RTstruct
%Create the figure
hf = figure('units','normalized','position',[.2 .2 .6
.6],'Color','none');
%Assign bg image to im1
im1=AxialImage(:,:,x);
%Assign fg image to im2
im2=RTstruct(:,:,x);
%Open the image
hax1 = imagesc(im1);
%Set the aspect ratio
axis('image')
axis off
hold on
%Set the colormap for the bg as grayscale
cmap1 = colormap(gray);
ax1 = gca;
set(ax1,'Color','none')
%Set the fg axes
ax2 =axes('Position',get(ax1,'Position'));
%Open the fg images and get its handle
hax2 = imagesc(im2);
%Set the aspect ratio
axis('image')
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axis off
%Overlay the ax2 ontop of ax1
set(ax2,'YAxisLocation','right','Color','none','XTickLabel',[]);
set(ax2,'XLim',get(ax1,'XLim'),'Layer','top')
%Set the cololmap for the fg image as jet
cmap2=colormap(jet);
%Splice the two colormaps into one
colormap([cmap1;cmap2]);
%Determine the length of the entire colormap
CmLength
= length(colormap);
%Set the beginning position of the colormap
BeginSlot1 = 1;
%Set the end position of the first colormap scale
EndSlot1
= length(cmap1);
%Set the beginning position of the second colormap scale
BeginSlot2 = EndSlot1 + 1;
%Set the end position of the second colormapr scale
EndSlot2
= CmLength;
%Determine the current color limits for the bg image
CLim1 = [min(min(min(AxialImage))) max(max(max(AxialImage)))];
%Determine the current color limits for the fg image
%CLim2 = [min(min(min(RTstruct))) max(max(max(RTstruct)))];
%Set the CLim2 for presentation plots, same scale
CLim2 = [.4 2.0];
%Set the color limits for the bg image
set(ax1,'CLim',newclim(BeginSlot1,EndSlot1,CLim1(1),...
CLim1(2),CmLength));
%Set the color limits for the fg image
set(ax2,'CLim',newclim(BeginSlot2,EndSlot2,CLim2(1),...
CLim2(2),CmLength));
%Set the transparency
set(hax2, 'AlphaData',RTalphamap(:,:,x));
%Set the position of the color
cbar_axes = colorbar('Position',[.835 .11 .062 .815]);
%Set the CT label for the colorbar
Ylabel = str2num(get(cbar_axes,'YTickLabel'));
f=int16(1);
if rem(size(Ylabel,1),2)==1
%Number of labels
LabCnt = int16(round(size(Ylabel,1)/2)-1);
%The colorbar has an odd number of labels
for i=LabCnt:-1:1
Ylabel(i,1)= CTmax - (CTrange/LabCnt)*f;
f=f+1;
end
else
%Number of labels
LabCnt = int16(size(Ylabel,1)/2);
%The colorbar has an even number of labels
for i=LabCnt:-1:1
Ylabel(i,1) = CTmax - (CTrange/(LabCnt+1))*f;
f=f+1;
end
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end
set(cbar_axes,'YTickLabel',num2str(Ylabel),'YColor',[.968 .968 .968]);

Metabolic Dose

The following script was utilized to construct voxel based dose-metabolic
response curve.

function MetabolicDose_Batch(PtData, PtName, PathName, drun, Norm)
%%!!!!!!!
%%

MUST!!! be used with Main_Head_Batch.m or define the golobal
varibles below!!!!!!

%The following algorithm will create a dose-uptake response curve for
the
%sturctures contained within the *.roi file based upon the metabolic
dose
%metric. Bins are created by binning the dose to achieve uniformity
and
%the computing the metabolic dose metric and fractional uptake for said
%regions.
%Define the type of analysis
%BinType = 1 - Dose binned analysis
%BinTpye = 2 - Function binned analysis
%BinType = 3 - Metabolic dose binned analysis
BinType = 3;
SumFlag = 0;
if isdir([PathName,'\','MetabolicDoseBin_data'])
d = datestr(now,30);
mkdir(PathName,['MetabolicDoseBin_data_',d]);
mkdir(PathName,['MetabolicDoseBin_plot_',d]);
mkdir(PathName,['MetabolicDoseBin_txtimg_',d]);
dataWritePath = [PathName,'\','MetabolicDoseBin_data_',d];
plotWritePath = [PathName,'\','MetabolicDoseBin_plot_',d];
txtimgWritePath = [PathName,'\','MetabolicDoseBin_txtimg_',d];
else
mkdir(PathName,'MetabolicDoseBin_data');
mkdir(PathName,'MetabolicDoseBin_plot');
mkdir(PathName,'MetabolicDoseBin_txtimg');
dataWritePath = [PathName,'\','MetabolicDoseBin_data'];
plotWritePath = [PathName,'\','MetabolicDoseBin_plot'];
txtimgWritePath = [PathName,'\','MetabolicDoseBin_txtimg'];
end
%Define the header string that all files will use in this function
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HeaderStr={'Patient: '; ...
'Dose_min(cGy)'; ...
'Dose_max(cGy)'; ...
'Dose_mean(cGy)'; ...
'Dose_std(cGy)'; ...
'SUV1_min'; ...
'SUV1_max'; ...
'SUV1_mean'; ...
'SUV1_std'; ...
'SUV2_min'; ...
'SUV2_max'; ...
'SUV2_mean'; ...
'SUV2_std'; ...
'Metabolic_Dose_min(cGyMBq/mL)'; ...
'Metabolic_Dose_max(cGyMBq/mL)'; ...
'Metabolic_Dose_mean(cGyMBq/mL)'; ...
'Metabolic_Dose_median(cGyMBq/mL)'; ...
'Metabolic_Dose_std(cGyMBq/mL)'; ...
'Lilliefors_MetabolicDose';...
'Kurtosis_MetabolicDose';...
'Skewness_MetabolicDose';...
'Fractional_Uptake_min'; ...
'Fractional_Uptake_max'; ...
'Fractional_Uptake_mean'; ...
'Fractional_Uptake_std'; ...
'Lilliefors_FractionalUptake';...
'Kurtosis_FractionalUptake';...
'Skewness_FractionalUptake';...
'VolumeFraction';...
'VoxelCount'};
%This code will cause problems if not used with Main_Head_Batch
TempIndex=strmatch('Patient: ', HeaderStr);
HeaderStr{TempIndex}=['Patient: ', PtName];
%Gather all ROIs present in PtData structure
FieldNames=fieldnames(PtData);

for j=1:length(FieldNames)
%disp([PtName,' ',FieldNames{j}])
tempFieldName = FieldNames{j};
%Sort the ROI by physical dose
PtData.(FieldNames{j}) = sortrows(PtData.(FieldNames{j}),4);
%Identify voxels that received less than 500 cGy
DoseFilter = find(PtData.(FieldNames{j})(:,4)<500);
%Remove voxels receiving less than 500 cGy from analysis
PtData.(FieldNames{j})(DoseFilter(:,1),:) = [];
%If all physical dose is below threshold, do not analyze
if isempty(PtData.(FieldNames{j}));
continue;
end
%Compute the Metabolic dose metric for each voxel
PtData.(FieldNames{j})(:,8) =
PtData.(FieldNames{j})(:,4).*PtData.(FieldNames{j})(:,5);
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if
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||...
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||...
strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROI40Node'
)||...
strcmp(tempFieldName,'ROI50Node')||strcmp(tempFieldName,'ROI40NAirlmtd'
)||...
strcmp(tempFieldName,'ROI50NAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||...
strcmp(tempFieldName,'ROIGTVNodesAir')||strcmp(tempFieldName,'ROIGTVnod
e')||...
strcmp(tempFieldName,'ROIRefBrainstem'));
continue;
if ((max (PtData.(FieldNames{j})(:,8)) - min
(PtData.(FieldNames{j})(:,8)))>100000);
DoseBin = (min (PtData.(FieldNames{j})(:,8)):10000:max
(PtData.(FieldNames{j})(:,8)));
else
DoseBin = (min (PtData.(FieldNames{j})(:,8)):2000:max
(PtData.(FieldNames{j})(:,8)));
end
elseif
(strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL
')||...
strcmp(tempFieldName,'ROIIpsilateralParotid')||strcmp(tempFieldName,'RO
IContralateralParotid')||...
strcmp(tempFieldName,'ROIParotids')||strcmp(tempFieldName,'ROISMG'))
DoseBin = (min (PtData.(FieldNames{j})(:,8)):2000:max
(PtData.(FieldNames{j})(:,8)));
else
continue;
if strcmp(tempFieldName,'ROI70Gy')
if ((max (PtData.(FieldNames{j})(:,8)) - min
(PtData.(FieldNames{j})(:,8)))>100000);
DoseBin = (min
(PtData.(FieldNames{j})(:,8)):10000:max (PtData.(FieldNames{j})(:,8)));
else
DoseBin = (min
(PtData.(FieldNames{j})(:,8)):2000:max (PtData.(FieldNames{j})(:,8)));
end
else
continue;
end
%
if ((max (PtData.(FieldNames{j})(:,8)) - min
(PtData.(FieldNames{j})(:,8)))<500)
%
%Dose bin size set at 10 cGy
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%
DoseBin = (min (PtData.(FieldNames{j})(:,8)):10:max
(PtData.(FieldNames{j})(:,8)));
%
%elseif ((max (PtData.(FieldNames{j})(:,8)) - min
(PtData.(FieldNames{j})(:,8)))>)
%
else
%
%Dose bin size set at 500 cGy
%
DoseBin = (min (PtData.(FieldNames{j})(:,8)):500:max
(PtData.(FieldNames{j})(:,8)));
%
end
end
%Create the dose bin label i.e., make the bins integers and
eliminate
%trailing and leading zeros
DoseName = strtrim(cellstr(num2str(uint32(DoseBin'))));
%Compute the total number of pixels in the ROI for fractional
volume
%purposes
VolumeTotal = size(PtData.(FieldNames{j}),1);
%Open the text file for writing fDVH data
fid = fopen([dataWritePath,'\', FieldNames{j},'.out'],'wt');
if
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||...
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||...
strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||...
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||...
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||...
strcmp(tempFieldName,'ROIParotids'));
%Open file for writing text image data
fid2 = fopen([txtimgWritePath,'\',
tempFieldName,'.txtimg'],'wt');
end
%Write the header to text file
for k=1:length(HeaderStr)
if k == 1
fprintf(fid, '%-35s\n\n', HeaderStr{k});
elseif k == (length(HeaderStr))
fprintf(fid, '%-35s\n', HeaderStr{k});
else
fprintf(fid, '%-35s', HeaderStr{k});
end
end
%Initialize the text image matrix
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ImgTxtData = [];
BinData = zeros(29,size(DoseBin,2));
for i=1:(size(DoseBin,2));
MetDose = [];
%Identify indecies of data falling into volume-dose bins
if i == size(DoseBin,2);
%Finds indicies for the last dose bin
PtHisto.(FieldNames{j}).DoseBin{i} =
find((PtData.(FieldNames{j})(:,8) >= DoseBin(i)));
else
%Finds indicies for all bins except last bin
PtHisto.(FieldNames{j}).DoseBin{i} =
find((PtData.(FieldNames{j})(:,8) >= DoseBin(i)) &
(PtData.(FieldNames{j})(:,8) < DoseBin(i+1)));
end
%Extract the needed data to individual volume-dose bins
PtHisto.(FieldNames{j}).data.(['V' DoseName{i}]) =
PtData.(FieldNames{j})(PtHisto.(FieldNames{j}).DoseBin{1,i},:);
%If the dose bin is empty, simply set datum as NaN
if isempty(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
BinData(1:29,i) = NaN;
continue;
elseif size(PtHisto.(FieldNames{j}).data.(['V' DoseName{i}]),1)
< 4;
%Write the Dose data to matrix
BinData(1,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(2,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(3,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(4,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
%Write SUV1 data to matrix
BinData(5,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(6,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(7,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(8,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
%Write SUV2 data to matrix
BinData(9,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(10,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(11,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(12,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
%Write Metabolic Dose data to matrix
MetDose = PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4) .* ...;
PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,5);
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BinData(13,i) = min(MetDose);
BinData(14,i) = max(MetDose);
BinData(15,i) = mean(MetDose);
BinData(16,i) = median(MetDose);
BinData(17,i) =
((mean(MetDose)^2)*((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))/...;
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5)))^2)+...;
(var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4))/...;
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4)))^2)))^0.5;
%Do not perform Lilliefors
BinData(18,i) = NaN;
%Do not perform Kurtosis
BinData(19,i) = NaN;
%Do not perform Skewness
BinData(20,i) = NaN;
%Write Fractional Uptake data to matrix
BinData(21,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
BinData(22,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
BinData(23,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
%Write the std of F.U., using propagation of error with
%correlated data term
FU = cov(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5),...
PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,6));
BinData(24,i) = ((mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7)))^2*...
((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5)))^2)+...
((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6)))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6)))^2)-...
(2*FU(1,2)/(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))*...
mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6))))))^0.5;
%Do not perform Lilliefors
BinData(25,i) = NaN;
%Do not perform Kurtosis
BinData(26,i) = NaN;
%Do not perform Skewness
BinData(27,i) = NaN;
%Write fractional volume of current bin to matrix
BinData(28,i) = size(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}]),1)/VolumeTotal;
%Write number of voxels of current bin to matrix
BinData(29,i) = size(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}]),1);
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%Do not perform tests for normality of bin
else
%Write the Dose data to matrix
BinData(1,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(2,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(3,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
BinData(4,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4));
%Write SUV1 data to matrix
BinData(5,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(6,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(7,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
BinData(8,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5));
%Write SUV2 data to matrix
BinData(9,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(10,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(11,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
BinData(12,i) = std(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6));
%Write Metabolic Dose data to matrix
MetDose = PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4) .* ...;
PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,5);
BinData(13,i) = min(MetDose);
BinData(14,i) = max(MetDose);
BinData(15,i) = mean(MetDose);
BinData(16,i) = median(MetDose);
BinData(17,i) =
(mean(MetDose)^2*((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5)))^2)+...
(var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,4)))^2)))^0.5;
%Perform Lilliefors test for goodness of fit to normal
%distribution to metabolic dose data
BinData(18,i) = lillietest(MetDose);
%Determine sample kurtosis, normal = 3, more outlier
prone>3,
%less outlier prone<3 for metabolic dose data
BinData(19,i) = kurtosis(MetDose);
%Determine sample skewness, if negative data are spread to
left
%of mean, if positive data are to right of mean, zero is
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%symmetric distribution
BinData(20,i) = skewness(MetDose);
%Write Fractional Uptake data to matrix
BinData(21,i) = min(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
BinData(22,i) = max(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
BinData(23,i) = mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
%Write the std of F.U., using propagation of error with
%correlated data term
FU = cov(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5),...
PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,6));
BinData(24,i) = ((mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7)))^2*...
((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5)))^2)+...
((var(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6)))/...
(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6)))^2)-...
(2*FU(1,2)/(mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,5))*...
mean(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,6))))))^0.5;
%Perform Lilliefors test for goodness of fit to normal
%distribution
BinData(25,i) =
lillietest(PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,7));
%Determine sample kurtosis, normal = 3, more outlier
prone>3,
%less outlier prone<3
BinData(26,i) = kurtosis(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
%Determine sample skewness, if negative data are spread to
left
%of mean, if positive data are to right of mean, zero is
%symmetric distribution
BinData(27,i) = skewness(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,7));
%Write fractional volume of current bin to matrix
BinData(28,i) = size(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}]),1)/VolumeTotal;
%Write number of voxels of current bin to matrix
BinData(29,i) = size(PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}]),1);
end
if
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||...
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||...
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strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||...
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||...
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||...
strcmp(tempFieldName,'ROIParotids'));
tempMetDoseName =
char(strtrim(cellstr(num2str(uint32(BinData(15,i))))));
tempFracUptkName =
char(strtrim(cellstr(num2str(uint32(BinData(23,i))))));
tempdosename = char(DoseName(i));
%Create histogram of dose bin
SubPlothisto(tempFieldName, tempMetDoseName,
tempFracUptkName, tempdosename, PtHisto, plotWritePath, MetDose, Norm,
SumFlag);
clear tempdosename tempMetDoseName tempFracUptkName FU
%Create temporary matrix of current dose bin's x, y, and z
indicies
tempTxtData = (PtHisto.(FieldNames{j}).data.(['V'
DoseName{i}])(:,1:3))';
%Place the dose bin's mean fractional uptake as the pixel
value
tempTxtData(4,:) = BinData(23,i);
%Place the mean metabolic dose for this region
tempTxtData(5,:) = BinData(15,i);
%Place the mean SUV1 for this region
tempTxtData(6,:) = BinData(7,i);
%Place the mean SUV2 for this region
tempTxtData(7,:) = BinData(11,i);
%Write image data to text file
fprintf(fid2, '%-15.0f%-15.0f%-15.0f%-15.4f%-15.4f%-15.4f%15.4f\n', tempTxtData);
tempTxtData=[];
end
end
%Eliminate the NaNs from the BinData matrix
EmptyBinIndex = isnan(BinData(1,:));
BinData(:,EmptyBinIndex) = [];
%Write fDVH plot to file calling subfunction
SubPlotfDVH(tempFieldName, BinData, plotWritePath, Norm, BinType);
%Write differential dose volume histogram
SubPlotdiffDVH(tempFieldName, BinData, plotWritePath, Norm,
BinType);
%Write cummulative dose volume histogram
SubPlotcummDVH(tempFieldName, BinData, plotWritePath, Norm,
BinType);
if
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||...
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||...
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strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||...
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||...
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||...
strcmp(tempFieldName,'ROIParotids'));
%Close the text image
fclose(fid2);
end
%Write the BinData matrix to
fprintf(fid,'%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%35.4f%-35.4f\n',BinData);
fclose(fid);
%Write data to summary file for entire patient cohort
summaryfile(tempFieldName, BinData, PathName, drun, PtName,
BinType,PtData);
%Write unbinned data to summary file for entire cohort
%Unbinnedsummaryfile(tempFieldName, PtData, PathName, drun, PtName,
BinType);
clear PtHisto DoseBin DoseName VolumeTotal BinData tempFieldName
tempTxtData;
end
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